

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/11, C07K 14/705, 16/18, C12Q 1/02, 1/68, A61K 48/00, G01N 33/53, 33/50	A1	(11) International Publication Number: WO 99/64589 (43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/GB99/01798 (22) International Filing Date: 8 June 1999 (08.06.99) (30) Priority Data: 60/088,958 11 June 1998 (11.06.98) US (71) Applicant: ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). (72) Inventors: GHILDYAL, Namit; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). PAN- CHAMOORTHY, Govindaswamy; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). (74) Agent: PHILLIPS, Neil, Godfrey, Alasdair; Zeneca Pharmaceu- ticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: HUMAN RECEPTOR TYROSINE KINASE (57) Abstract An isolated and purified human receptor tyrosine kinase is described. A cDNA sequence which encodes the native polypeptide is disclosed as well as the structural coding region and the amino acid residue sequence of the tyrosine kinase. Methods are provided which employ novel sequences to identify compounds that modulate the biological and/or pharmacological activity of the tyrosine kinase and hence regulate cellular and tissue physiology. Biologically-effective antisense molecules, as well as dominant negative mutant versions of the kinase, are described which are suitable for therapeutic use. The invention is also related to the diagnosis, study, prevention, and treatment of pathophysiological disorders related to or mediated by the biological molecule.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

HUMAN RECEPTOR TYROSINE KINASE

Applicants herein claim priority under Title 35 USC § 119(e) from the Provisional Application, HUMAN RECEPTOR TYROSINE KINASE, Serial No.60/088,958, filed June 11,
5 1998 in the United States Patent and Trademark Office, which is incorporated herein by reference.

Field Of The Invention

The present invention relates to nucleic acid and amino acid sequences pertaining to a novel receptor tyrosine kinase and to the use of these sequences to identify compounds that
10 modulate a biological and/or pharmacological activity of the native biomolecule. The invention also relates to biologically-effective antisense molecules, as well as dominant negative mutant versions of the receptor tyrosine kinase which are suitable for therapeutic use. The invention is also related to the diagnosis, study, prevention, and treatment of pathophysiological disorders related to or mediated by the receptor tyrosine kinase.

15 Background Of The Invention

Pathologic angiogenesis occurs under many conditions and is thought to be induced by local ischemia. Diseases in which angiogenesis is thought to play a critical role in the underlying pathology include: ocular diseases such as diabetic retinopathy, retinopathy or prematurity and age-related macular degeneration; vascular diseases such as ischemic heart
20 disease and atherosclerosis; chronic inflammatory disorders such as psoriasis and rheumatoid arthritis; and solid tumor growth. A recent review primarily focuses on the role of RTKs in tumor angiogenesis. Shawver, L.K., *et al.*, *Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis*, Drug Discovery Today (Elsevier Science Ltd.), 2(2):50 (1997). The review primarily addresses the role of growth factors and their receptor tyrosine kinases
25 (RTKs) in the regulation of microvessel physiology as they relate to the angiogenic process. New blood vessel growth is required for the growth and metastasis of solid tumors. The significance of angiogenesis in human tumors has been highlighted by recent studies that relate the angiogenic phenotype to patient survival. These studies found that the number of microvessels in a primary tumor has prognostic significance in breast carcinoma, bladder
30 carcinomas, colon carcinomas and tumors of the oral cavity. Anti-angiogenic agents potentially have broad applications in the clinic. *Id. See, also*, Herz, Jeffrey M., *et al.*,

Molecular Approaches to Receptors as Targets for Drug Discovery, J. of Receptor & Signal Transduction Research, 17(5):671 (1997).

RTKs (also known as growth factor receptors) play an important role in many cellular processes. All of these molecules have an extracellular ligand-binding domain. Upon ligand binding, receptors dimerize, the tyrosine kinase is activated and the receptors become autophosphorylated. Ulrich, A., et al., *Cell*, 61:203 (1990). The cascade triggered by RTK activation modulates cellular events, determining proliferation, differentiation and morphogenesis in a positive or negative fashion. Disturbances in the expression of growth factors, their cognate RTKs, or constituents of downstream signaling pathways are commonly associated with many types of cancer. Gene mutations giving rise to altered protein products have been shown to alter the regulatory mechanisms influencing cellular proliferation, resulting in tumor initiation and progression. Shawver, L.K., et al., *Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis*, DDT (Elsevier Science Ltd.), 2(2):50 (1997).

One strategy for interfering with receptor signaling is to inhibit ligand binding. This can be accomplished with specific receptor-binding antagonists such as ligand fragments, or with nonspecific antagonists such as suramin, with neutralizing antibodies to either the ligand or receptor, or with an excess of soluble receptor or ligand-binding protein, which will sequester the ligand. A second strategy for interfering with receptor signaling is to block signal transduction by over-expression of a dominant-negative receptor. Because receptor kinases typically dimerize to induce signal transduction through transphosphorylation, prevention of receptor dimerization due to overexpression of kinase-deficient receptors will attenuate activation of signaling. Receptors can be made kinase-deficient by introduction of a point mutation in amino acids critical for kinase function, or deletion of the kinase or entire cytoplasmic domain. Another strategy for understanding receptor function involves depleting the receptor protein. This can be accomplished by the introduction of exogenous agents such as antisense oligonucleotides, antisense RNA, or ribozymes, all of which lead to degradation of the receptor mRNA and gradual depletion of the protein in the cell. *Id.*

The profound cellular effects mediated by tyrosine kinases and phosphotyrosine phosphatases have made them attractive targets for the development of new therapeutic molecules. It is known, for example, that the overexpression of tyrosine kinases, such as HER2, can play a decisive role in the development of cancer and that antibodies capable of blocking the activity of this enzyme can abrogate tumor growth. Slamon, D. J., et al., *Science*,

- 3 -

235:177 (1987); Drebin, *et al.*, *Oncogene* 2:387 (1988). More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642), vinylene-azaindole derivatives (PCT WO 94/14808) and 1-cyclopropyl-4-pyridyl-quinolones (U.S. Pat. No. 5,330,992) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Pat. No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Pat. No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer.

The availability of a novel human receptor tyrosine kinase species which is clearly implicated by a functional connection to disease will be ideal for such drug screening as well as diagnosis, study, prevention, and treatment of pathophysiological disorders related to the biological molecule.

15 Summary Of The Invention

The present invention is directed to a purified polynucleotide comprising a nucleic acid sequence which encodes a peptide having at least about 80% homology to a member selected from the group consisting essentially of: (SEQ ID NO:3, SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-422).

The present invention is also directed to a purified polynucleotide comprising a nucleic acid sequence which encodes a polypeptide comprising the sequence as depicted in SEQ ID NO:3 wherein position 147 (Lysine) of SEQ ID NO:3 is substituted or deleted.

Isolated and purified polynucleotides of the present invention include but are not limited to sequences comprising SEQ ID NO:1 and SEQ ID NO:2.

The current invention is directed to a purified polypeptide comprising the amino acid sequence as depicted in SEQ ID NO:3 or a variant of SEQ ID NO:3 having at least about 80% homology to a member selected from the group consisting essentially of: (SEQ ID NO:3, SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-422).

A preferred embodiment of the invention is an isolated and purified biologically effective antisense polynucleotide molecule comprising an oligomer in the range from about 12

to about 25 nucleotides in length which is complementary to a region within positions 67-148 and 1333-1414 of SEQ ID NO:1.

The invention is further directed to an expression vector, as well as host cells which harbor the expression vector, for the expression of a polypeptide, wherein said vector
5 comprises a nucleic acid sequence which encodes a polypeptide as depicted in SEQ ID NO:3 or a pharmacologically and/or biologically active or biologically effective derivative thereof.

The instant invention is further directed to methods of identifying compounds that modulate a biological and/or pharmacological activity of a tyrosine kinase, which comprise:

- (a) combining a candidate compound modulator of activity with a polypeptide having
10 the sequence as depicted in SEQ ID NO:3 or a variant thereof, and
- (b) measuring an effect of the candidate compound modulator on the biological and/or pharmacological activity of the polypeptide.
- (c) The present invention is also directed to compounds identified by means of methods provided wherein said compound modulates the biological and/or pharmacological activity of
15 a tyrosine kinase.

Additionally, the invention is directed to methods of treatment of a patient in need of such treatment for a condition which is mediated by a tyrosine kinase, comprising administering: (a) an effective amount of a compound identified by means of provided methods; and/or (b) an effective amount of a polynucleotide which encodes a biologically
20 effective dominant negative mutant polypeptide comprising the sequence as depicted in SEQ ID NO:3 or a contemplated variant thereof; and/or (c) an effective amount of a biologically effective antisense molecule derived from the complement of SEQ ID NO:1.

Detailed Description Of The Invention

Unless defined otherwise, all technical and scientific terms used herein have the same
25 meaning as is commonly understood by one of skill in the art to which this invention belongs. All publications and patents referred to herein are incorporated by reference.

Biological activity as used herein in reference to the tyrosine kinase of the present invention refers to the kinase activity of the biomolecule and/or to the performance of any one or more of the functions including but not limited to the ability to autophosphorylate, to
30 phosphorylate a substrate, to bind ATP, and to mediate the activation of Cdc2 kinase.

Pharmacological activity as used herein in reference to the tyrosine kinase of the present invention refers to the direct or indirect transcriptional activation of one or more genes;

- 5 -

as well as the ability to mediate any one or more of the physiological conditions including but not limited to mitosis, cell differentiation, proliferation, oncogenic transformation, neoplasia, macrophage regulation, endothelial cell regulation, fibroblast regulation, cytoskeletal structure, metastases, cell aggregation, cell motility, cytokinesis, cancer, angiogenesis, cell senescence,
5 acute and chronic inflammation, auto-immune disorders, arthritis, neurogenerative processes, allergic response, stress response, secretion, apoptosis, cachexia, neurological disorders, peripheral vascular disease, atherosclerosis, heart disease, asthma, and atheroma.

Dominant negative mutant as used herein refers to a polypeptide or a nucleic acid coding region sequence which has been changed with regard to at least one position in the
10 sequence, relative to the corresponding wild type native version at a position which changes an amino acid residue position at an active site required for biological and/or pharmacological activity of the native peptide. Dominant negative mutants of SEQ ID NO:3 contemplated herein include, but are not limited to, polypeptide species which manifest any change with regard to any change in the residue Lys(K)¹⁴⁷.

15 Biologically effective as used herein in reference to antisense nucleic acid molecules as well as dominant negative mutant nucleic acid coding regions and dominant negative mutant peptides refers to the ability of these molecules to modulate the biological and/or pharmacological activity of the tyrosine kinase of the present invention, including direct or indirect modulation of transcriptional activation of one or more genes, and/or
20 transcription/translation of nucleic acid coding regions of the tyrosine kinase of the present invention. *Biologically effective* antisense molecules as well as nucleic acids which encode biologically effective dominant negative mutant versions of SEQ ID NO:3, or derivatives thereof, are preferred embodiments of the present invention.

As depicted as used herein refers the sequence as well as inherent derivatives thereof,
25 e.g., functional derivative that demonstrate or perform substantially the same biological and/or pharmacological activity in substantially the same way. 'As depicted' is therefore intended to encompass biologically and/or pharmacologically active truncated versions clearly derived from the sequences disclosed and characterized herein (e.g., evidenced domains) as well as chimeric sequences which contain one or more of them.

30 Variant as used herein refers to sequences substantially as shown having changes, e.g., a polypeptide sequence comprising a sequence which differs from the sequence referred to by at least one amino acid substitution, addition, or deletion, preferably a conservative amino acid

- 6 -

substitution, that demonstrate or perform substantially the same biological and/or pharmacological activity in substantially the same way, as well as truncated versions of these variants. However, variant as used herein is intended to encompass all contemplated *biologically effective dominant negative mutants*, several species of which are set forth herein.

5 The term modulation is used herein to refer to the capacity to either enhance or inhibit a function of a biological molecule including, but not limited to, a biological and/or pharmacological activity of a tyrosine kinase molecule, or to the capacity to either enhance or inhibit a functional property of a nucleic acid coding region. Modulate physiology as used herein refers to the biophysiological regulation of cells and/or tissue and the treatment of
10 pathophysiological disorders related thereto.

Direct administration as used herein refers to the direct administration of nucleic acid molecules, peptides, or compounds as well as contemplated derivatives/variants of the present invention. Direct administration includes but is not limited to *ex vivo* as well as *in vivo* gene therapy techniques.

15 Purified as used herein refers to molecules, either nucleic acid or amino acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

Expression vector as used herein refers to nucleic acid vector constructions to direct the transcription of nucleic acid regions in host cells. Expression vectors include but are not
20 limited to plasmids, retroviral vectors, viral and synthetic vectors.

Transformed host cells as used herein refer to cells which harbor one or more nucleic acids of the present invention.

RTKs

A wide variety of polypeptide growth factor receptors that possess intrinsic tyrosine
25 kinase activity have now been characterized. Activated receptor tyrosine-kinases (RTKs) undergo dimerization and initiate signaling through tyrosine-specific phosphorylation of diverse intermediates, activating a cascade of intracellular pathways that regulate phospholipid and arachidonate metabolism, calcium mobilization, protein phosphorylation (involving other protein kinases), and transcription regulation. The growth factor-dependent tyrosine kinase
30 activity of the RTK cytoplasmic domain is the primary mechanism for generation of intracellular signals that initiate multiple cellular responses. Cellular responses mediated by RTKs include alterations in gene expression, cell proliferation, cytoskeletal architecture, cell

metabolism, differentiation and cell survival. Receptor-tyrosine kinases consist of an amino-terminal extracellular ligand binding domain, a transmembrane domain, and a carboxyl-terminal intracellular tyrosine kinase domain. Herz, Jeffrey M., et al., *Molecular Approaches to Receptors as Targets for Drug Discovery*, J. of Receptor & Signal Transduction Research, 5 17(5):671 (1997).

Although there is a tremendous diversity among the numerous members of the RTK family, the signaling mechanisms used by these receptors share many common features. Biochemical and molecular genetic studies have shown that binding of the ligand to the extracellular domain of the RTK rapidly activates the intrinsic tyrosine kinase catalytic activity of the intracellular domain. Enzymatic activity of the RTK kinase domain is essential for signal 10 transduction. The increased activity also leads to phosphorylation of a number of intracellular substrates and activation of numerous downstream signaling molecules. Examples of proteins that are frequently activated include: phospholipase-C- γ (PLC- γ), phosphatidylinositol 3-kinase (PI-3kinase), GTPase activating protein, pp60^{c-arc} protein tyrosine kinase, p21-ras and 15 others. *Id.*

The role of receptor tyrosine kinases (RTKs) in the formation of new blood vasculature associated with human disease has provided a strong rationale to identify ways of inhibiting the function of these enzymes. The vast majority of efforts have focused on the inhibition of FGF and VEGF receptors. Other RTKs have been implicated in angiogenesis. These targets would 20 be amenable to many of the approaches that have been taken using the FGF and VEGF receptor targets. The therapeutic modalities that have been studied for abrogation of FGF- and VEGF-dependent signaling include the use of nucleotides (gene therapy and antisense), proteins, (antibodies, receptor and ligand decoys) low-molecular-weight compounds, as well as expression of a dominant-negative forms. The use of low-molecular-weight compounds to 25 treat angiogenesis represents an ever-expanding area of research activities. Shawver, L.K., *et al.*, *Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis*, DDT (Elsevier Science Ltd.), 2(2):50 (1997).

Rheumatoid arthritis, although characterized by inflammation and immunoproliferation, is another disease in which angiogenesis has been implicated in the disease process because 30 RTKs represent proteins with enzymatic function, they lend themselves to a pharmacological intervention with small-molecule compounds. *Id.*

Human Receptor Tyrosine Kinase

A 2607 base pair cDNA sequence, SEQ ID NO:1, which pertains to the human receptor tyrosine kinase SEQ ID NO:3 is set forth herein. The 1269 base pair structural region, ATG to TGA, SEQ ID NO:2, which encodes SEQ ID NO:3 (422 amino acids), is
5 contained in SEQ ID NO:1.

The physical sequence (SEQ ID NO:3) contains all of the tyrosine kinase signature sequences, juxtamembrane sequences, transmembrane sequences and extracellular sequences that show structural similarity to the known receptor tyrosine kinases, e.g., FGF-R, EGF-R, PDGF-R, IGF-R, VEGF-R, FLK, FLT, TIE, as well as others known in the art. *See, e.g.,*
10 Dionne, C.A., *et al.*, EMBO, 9:2685 (1990); Berchuck, A., *et al.*, Am. J. Obstet. Gynecol., 161:1247 (1989); Kraus, M.H., *et al.*, Ann. NY Acad. Sci., 551:320 (1988); Bishop, J.M., *et al.*, Science, 235:305 (1987). SEQ ID NO:3 demonstrates attributes of the polypeptide which include a 24-residue transmembrane domain which separates an extracellular portion from the cytoplasmic domain. The cytoplasmic domain includes a
15 juxtamembrane sequence immediately followed by the tyrosine kinase domain containing eleven subdomains. The signature sequences demonstrated in the novel human receptor tyrosine kinase signal transduction molecule (SEQ ID NO:3) are each of the Subdomains I-XI.

The role of receptor tyrosine kinases in cellular proliferation, *inter alia*, has led to the belief that RTKs have significant roles in mediation of disease and accordingly have significant
20 potential as specific therapeutic targets. Accordingly, modulating agents of specific RTK kinase activity and/or receptor activity are highly sought after in the pharmaceutical industry as candidate development compounds. Receptor Tyrosine Kinase molecules that are particularly characteristic of disease tissue, e.g., adenocarcinoma, (e.g., SEQ ID NO:3) serve as paramount candidates toward diagnosis of disease conditions as well as targets for modulation of tissue
25 physiology.

SEQ ID NO:1 has been mapped to chromosome 12p12.3 using Stanford G3 radiation hybrid panel by means of cell clones obtained from Research Genetics, Huntsville, AL. Stewart *et al.*, Genome Res., 7, 422 (1997). Cytogenetic abnormalities and loss of heterozygosity 12p12 have been shown to occur in a large number of tumor types in addition
30 to adenocarcinomas e.g. germ cell tumors, oral SCC, ovarian Ca, acute lymphocytic leukemia, and testicular germ cell tumors. Chromosome 12p12-p13 region has been shown to be amplified (4-11 copies) in a large number of tumors.

- 9 -

SEQ ID NO:1 demonstrates a total of 14 GT repeat sequences between positions 2125 and 2152. DNA sequencing of the corresponding genomic DNA from 27 unrelated Caucasians showed 11,12,13,14 and 15 copies of the GT repeat in the tyrosine kinase gene corresponding to SEQ ID NO:1 from 27 Caucasians with the following respective frequencies: 6/54; 2/54; 5 17/54; 16/54; and 13/54. No homozygotes were observed for any allele. This variable number CA/GT repeat can be used as a genetic marker for the receptor tyrosine kinase gene and for the chromosomal 12p12.3 for both disease association studies or loss of heterozygosity studies. Each of these alleles is intended to be within the scope of the claims appended hereto (e.g., PCR primers which can readily be constructed therefrom by a person of ordinary skill for 10 diagnostic methods and/or compositions). See, Example II.

Messenger RNA Pertaining To SEQ ID NO:1 Is Selectively Expressed In Human Forebrain.

Northern Blots obtained from Clontech (Palo Alto, CA) showed that one or more genes pertaining to the novel tyrosine kinase (SEQ ID NO:1) was selectively transcribed in 15 human forebrain tissue. High expression levels mRNA pertaining to the receptor tyrosine kinase were observed in the putamen and frontal lobe, in contrast to low to undetectable levels of transcript in cerebellum and medulla tissue.

SEQ ID NO:3 Is Overexpressed In A Large Number Of Tumors And Within The Brain Tissues Of Alzheimer Patients.

20 In collaboration with LifeSpan Biosciences (Seattle, WA) an immunocytochemical analysis was conducted by the employment of primary clinical samples and the antibody described herein. In normal tissues, the anti-SEQ ID NO:3 antibody demonstrates positive staining: in occasional neurons and glial cells and less frequently in their cell processes, within epithelium of the breast, the enterocytes and Schwann cells within the colon, APUD cells, 25 hepatocytes and kupffer cells, occasional Type 2 pneumocytes, and within macrophages, polymorphonuclear leukocytes, and a subset of lymphocytes, plasma cells and endothelial cells. The staining is negative in normal cell types including fibroblasts, adipocytes, goblet cells, the smooth muscle of the muscularis mucosa and muscularis propria, bile ducts, Type I pneumocytes, respiratory epithelium lining bronchioles, and prostatic glandular epithelium.

- 10 -

<u>TISSUE</u>	<u>DIAGNOSIS</u>	<u>AGE/SEX</u>
Brain	Normal	56/M
Brain	Normal	45/F
Breast	Normal	37/F
Breast	Normal	69/F
Colon	Normal	87/M
Colo-rectal	Normal	NA
Liver	Normal	46/M
Liver	Normal	75/M
Lung	Normal	ADULT
Lung	Normal	ADULT
Prostate	Normal	75/M
Prostate	Normal	46/M
Brain	Alzheimer's	90/F
Brain	Alzheimer's	81/M
Brain	Alzheimer's	76/F
Brain	Alzheimer's	80/F
Brain	Alzheimer's	60/F
Brain	Glioblastoma	52/M
Brain	Glioblastoma	44/M
Brain	Metastatic adenocarcinoma	70/M
Brain	Metastatic adenocarcinoma	49/M
Breast	Mucinous adenocarcinoma	
Breast	Infiltrating ductal carcinoma	
Breast	Infiltrating ductal carcinoma	
Breast	Infiltrating ductal carcinoma	
Breast	Infiltrating ductal carcinoma	
Colon	Well differentiated adenocarcinoma	89/M
Colon	Well differentiated adenocarcinoma	62/M
Colon	Well differentiated adenocarcinoma	77/M
Colon	Well differentiated adenocarcinoma	87/M
Rectum	Well differentiated adenocarcinoma	ADULT
Rectum	Well differentiated adenocarcinoma	ADULT
Rectum	Well differentiated adenocarcinoma	ADULT
Rectum	Well differentiated adenocarcinoma	ADULT
Rectum	Well differentiated adenocarcinoma	ADULT
Prostate	Adenocarcinoma	
Prostate	Poorly differentiated adenocarcinoma	
Prostate	Adenocarcinoma	
Prostate	Adenocarcinoma	
Prostate	Adenocarcinoma	
Lung	Adenocarcinoma, large cell poorly differentiated	53/F
Lung	Adenocarcinoma	65/M
Liver	Hepatocellular carcinoma	66/M
Liver	Hepatocellular carcinoma	82/M

- 11 -

Immunocytochemical Analysis Of Diseased Tissues (Anti-SEQ ID NO:3 Antibody)

- A. Cancer Tissues: Within neoplastic tissues, positive staining is demonstrated within two metastatic adenocarcinomas, positive staining within the five breast adenocarcinomas, positive staining within the five colon adenocarcinomas, positive staining within the five rectosigmoid adenocarcinomas, and positive staining within four of five prostatic adenocarcinomas, and three of five lung adenocarcinomas.
- B. Alzheimer's Tissues: The most dramatic staining with the anti receptor tyrosine kinase antibody was seen within Alzheimer's cases, both those with and without evidence of additional ischemic injury (i.e., evidence of recent or old infarct due to thromboembolism). The degree of staining within the neurons in the brain tissue and glial cells of relatively normal areas was faint, and similar to the faint occasional staining of cells and cell processes seen within the normal brains. In contrast to the faint staining within normal regions, there was a significantly increased level of signal in neurons and their associated cell processes in areas of injury. In addition, this increase in signal was not marked within the cell processes of the neuropil (rather than in the perinuclear cytoplasm of the neuron or astrocyte), producing halo-like rings in a perisomatic distribution around neurons, arborizing signals around astrocytes, and extensive, scattered deposits within the axons and cell processes of the neuropil. The increase in signal was seen within brains without artifacts with significant alzheimer's (particularly in regions with a heavy concentration of neuritic plaques or neurofibrillary tangles), and also in brains that contained regions of infarct in addition to the classic changes of Alzheimer's disease.

SEQ ID NO:3 Tyrosine Kinase Is Prominent In Prostate Cancer Tissue

- Based on the immunohistochemical findings (*supra*) prostate tumor tissues were obtained from the National Disease Research Interchange, Phila., PA. Western blot analysis of the tissue lysates confirmed the presence of two proteins (60 and 55 kDa) that reacted with the anti-SEQ ID NO:3 antibody. To further confirm whether these proteins are tyrosine phosphorylated, the prostate tumor sample was probed with anti-phosphotyrosine antibody. The anti-pY Ab bound to the 55 kDa protein (most prominent of all pY reacting proteins) in the prostate lysates which was found to be SEQ ID NO:3 upon stripping and re-probing the blot with anti-SEQ ID NO:3 antibody.

Antisense Oligonucleotides Derived From SEQ ID NO:1 Inhibit Proliferation Of A549 Cells

In view of the demonstration that the receptor tyrosine kinase is over expressed in tumor cell lines as well as primary clinical tumor tissues, pharmacological activity of the tyrosine kinase to induce cell proliferation was examined. Particularly we decided to investigate if antisense molecules complementary to regions of the receptor tyrosine kinase mRNA would have an effect on cell proliferation. Two example antisense oligonucleotides and their corresponding sense oligonucleotides (as controls) were synthesized which pertain to SEQ ID NO:1 positions 75-92 (oligo 1) and 1348-1365 (oligo 2) (further preferred embodiments of antisense molecules are set forth *infra*). The results of three independent experiments showed an average of 50 % inhibition of A549 cell proliferation upon administration of antisense oligo 1. Administration of antisense oligo 2 demonstrated a 20 % inhibitory effect. Each of the corresponding sense oligonucleotides (controls) demonstrated no effect upon proliferation. See Example III.

Biological Activity Studies Using CD8 Chimeric Constructs

To verify a particular biological activity of the receptor tyrosine kinase, chimeric constructs were generated comprised of the CD8 extracellular domain (CD8 is a well-known CTL specific cell surface protein) and the cytoplasmic domain of SEQ ID NO:3 (positions 26-422). These constructs were successfully expressed in COS-7 cells, NIH/3T3 fibroblasts and HEK293 cell lines as determined by western blotting using the anti-SEQ ID NO:3 antibody. It has been reported that the extracellular Cys residues of CD8 can form intermolecular disulfide bonds, accordingly it was hypothesized that the chimeric molecules would dimerize, after expression, bringing the two kinase domains together and stimulating *trans*-phosphorylation. An *in vitro* kinase assay was performed on the immunoprecipitated material obtained from transfected HEK293 cells. The results showed that low levels of tyrosine phosphorylation was observed on the chimeric proteins. To further understand the cellular function of the receptor tyrosine kinase, a preliminary experiment was conducted in U937 cells transfected with the chimeras followed by the activation with anti-CD8 Ab for 15 min (U937 cells were chosen as they are non-adherent cells and hence require low amounts of anti-CD8 Ab). Results were analyzed by western blot analysis using anti-phosphotyrosine (pY) Ab. While there were subtle differences in the pY patterns between the Ab activated and inactivated lanes, a prominent tyrosine phosphorylated 34 kDa protein was found to show a retarded mobility in

- 13 -

the anti-CD8 Ab activated sample. This 34 kDa protein was identified as Cdc2 upon re-probing the blot with anti-Cdc2 monoclonal Ab. This data clearly suggests that the novel receptor tyrosine kinase (SEQ ID NO:3) is linked to cell cycle progression.

Biological activity as used herein in reference to the tyrosine kinase of the present invention refers *inter alia* to mediation of the activation of Cdc2 kinase which, in turn mediates mitosis. See, e.g., Nishio K., *et al.*, *Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines*, *Anticancer Research*, 16(6B):3387 (1996); Vincent I., *et al.*, *Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain*, *Journal of Neuroscience*, 17(10):3588 (1997).

10 Expression Of The Receptor Tyrosine Kinase During Nerve Growth Factor (NGF) Withdrawal In PC12 Cells

Neuronal apoptosis as manifested in Alzheimer's disease is reported to be due in part to a non-dividing cell's uncoordinated attempt to reenter and progress through the cell cycle. Davis PK, *et al.*, *Journal of Neurochemistry*, 68:2338 (1997). This is believed to be relevant to the fact that the receptor tyrosine kinase described herein is over expressed in tissue pertaining to both Alzheimer's disease as well as in proliferating primary tumors; as well the demonstration that activation of SEQ ID NO:3 is linked to cell cycle progression. As a corollary, it was decided to determine whether the novel tyrosine kinase is over expressed in apoptotic neuronal cells. Others have demonstrated that the level of Cdc2 kinase increases fivefold in apoptotic PC12 cells after NGF deprivation. *Id.* PC12 cells were treated with NGF for 10 days. The cells were then washed in medium and incubated in the absence of NGF for one hour. Cells were harvested and lysates subjected to SDS-PAGE electrophoresis followed by Western blotting with an anti-SEQ ID NO:3 antibody. Results demonstrated that SEQ ID NO:3 protein was dramatically upregulated 1 hour after NGF withdrawal. These data suggest that expression of SEQ ID NO:3 may be involved in neuronal apoptosis.

Pharmacological Significance

The receptor tyrosine kinase described herein (SEQ ID NO:3) is highly likely to be an important regulator of cellular growth in particular tumors. Similar to the EGFR family of RTK's (EGF-R, FGF-R, PDGF-R, Flk-1/KDR, Flt-1, Tie-1 and Tek/Tie-2), the novel human signal transduction tyrosine kinase is over expressed in a variety of carcinomas (e.g., colorectal adenocarcinoma and lung carcinoma) and appears to be intimately related to, and may directly

- 14 -

contribute to, malignant tumor development. Thus, identification of modulation agents are contemplated for treatment of a variety of adenocarcinomas.

Compounds (e.g., small-molecules, peptides, analogs, mimetics) that modulate the pharmacological and/or biological activity of the receptor tyrosine kinase described herein are contemplated for use in the treatment of a wide variety of disease conditions including, but not limited to disease manifested by abnormal angiogenesis, peripheral vascular disease, arthritis, ocular diseases such as diabetic retinopathy, retinopathy or prematurity and age-related macular degeneration, ischemic heart disease and atherosclerosis, chronic inflammatory disorders such as psoriasis and rheumatoid arthritis; and solid tumor growth and metastasis.

SEQ ID NO:3, or nucleic acid sequences coding therefor, e.g. SEQ ID NO:1 and/or SEQ ID NO:2, have significant potential for the ability attenuate pathophysiological responses. The ability to screen for antagonists and/or agonists which modulate the biological and/or pharmacological activity of the native human tyrosine kinase molecule as described herein is significantly valuable toward the identification and development of therapeutic agents.

Moreover, diagnostic applications are readily apparent for the detection of pathophysiological conditions manifested by abnormal levels of molecules such as SEQ ID NO:2 and/or SEQ ID NO:3 by means of PCR sequence amplification and subsequent detection and/or antibody based assays, e.g., ELISA-based assays, which are well-known to those skilled in the art and readily performed provided the information disclosed herein.

The present invention relates to nucleic acid sequences and amino acid sequences of the tyrosine kinase and variants thereof and to the use of these sequences to identify compounds that modulate the biological and/or pharmacological activity of a signal transduction molecule.

Polynucleotide sequences which encode the tyrosine kinase as depicted in SEQ ID NO:3 and variants thereof contemplated herein are particularly preferred embodiment of the present invention. *Biologically effective* antisense molecules and nucleic acids which encode biologically effective dominant negative mutant versions of SEQ ID NO:3, or derivatives thereof, as well as dominant negative mutant versions of SEQ ID NO:3, and derivatives thereof, examples of each of which are described *infra*, are preferred embodiments of the present invention and are intended to fall within the scope of the claims appended hereto.

The present invention also provides a method of treatment for a patient in need of such treatment, *videlicet* for a patient who suffers a pathological condition mediated by the SEQ ID NO:3 tyrosine kinase or another signal transduction molecule or a downstream transcriptional

- 15 -

activator, comprising administering an effective amount of a biologically effective antisense nucleic acid molecule derived from SEQ ID NO:1 or SEQ ID NO:2; or administering an effective amount of a nucleic acid which encodes a biologically effective dominant negative mutant version of the tyrosine kinase; or administering a compound that modulates the
5 biological and/or pharmacological activity of SEQ ID NO:3 which was identified by a method described herein.

The present invention relates to nucleic acid sequences (e.g., SEQ ID NO:1 and SEQ ID NO:2) and amino acid sequences (e.g., SEQ ID NO:3; SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-
10 422) of the novel human signal transduction kinase as well as inherent derivatives thereof, e.g., functional derivative that demonstrate or perform substantially the same biological and/or pharmacological activity in substantially the same way. The invention is also intended to encompass biologically and/or pharmacologically active truncated versions clearly derived from the sequences disclosed and characterized herein (e.g., evidenced domains described *infra*) as
15 well as chimeric sequences which contain one or more of them.

Variants

The present invention relates to variants of nucleic acid sequences (e.g., SEQ ID NO:1 and SEQ ID NO:2) and amino acid sequences (e.g., SEQ ID NO:3) substantially as shown, which have changes, e.g., a polypeptide sequence comprising a sequence which differs from
20 the sequence referred to by at least one amino acid substitution, preferably a conservative amino acid substitution, that demonstrate or perform substantially the same biological and/or pharmacological activity in substantially the same way, as well as molecules which comprise truncated versions of these variants. However, variant as used herein is intended to encompass all contemplated *biologically effective dominant negative mutants*, several species of which
25 are set forth herein.

A preferred variant, as depicted in SEQ ID NO:3 for instance, is one having at least 80% amino acid sequence homology (identity) to SEQ ID NO:3; a more preferred variant is one having at least 90% amino acid sequence homology; and a most preferred variant is one having at least 95% amino acid sequence homology to the kinase molecule amino acid
30 sequence as depicted in SEQ ID NO:3 or a biologically and/or pharmacologically active substantial fragment thereof. Variants within the scope of this invention also include biologically-effective dominant negative mutants of these contemplated embodiments

- 16 -

A variant of the SEQ ID NO:3 human kinase molecule of the present invention may have an amino acid sequence that is different by one or more amino acid substitutions. Embodiments which comprise amino acid deletions and/or additions are also contemplated. The variant may have conservative changes (amino acid similarity), wherein a substituted
5 amino acid has similar structural or chemical properties, for example, the replacement of leucine with isoleucine. A variant may have nonconservative changes, e.g., replacement of a glycine with a tryptophan. Embodiments within the intended scope of the invention also include SEQ ID NO:3 having one or more amino acid deletions or insertions, or both. Guidance in determining which and how many amino acid residues may be substituted, inserted
10 or deleted without abolishing biological or proposed pharmacological activity may be reasonably inferred in view of this disclosure and may be further be found using computer programs well known in the art, for example, DNASTar software.

Amino acid substitutions of SEQ ID NO:3 may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic
15 nature of the residues as long as a biological and/or pharmacological activity of the native molecule is retained. However, amino acid substitutions are important to construct contemplated *biologically effective dominant negative mutants*, several species of which are set forth herein.

Negatively charged amino acids, for example, include aspartic acid and glutamic acid;
20 positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine; glycine, alanine; asparagine, glutamine; serine, threonine phenylalanine, and tyrosine. However, in the construction of biologically effective dominant negative mutants at least one amino acid residue position at an active site required for biological and/or pharmacological
25 activity in the native peptide is changed to produce an agent or entity having reduced activity or which is devoid of detectable native wild type activity.

Suitable substitutions of amino acids include the use of a chemically derivatized residue in place of a non-derivatized residue. D-isomers as well as other known derivatives may also be substituted for the naturally occurring amino acids. See, e.g., U.S. Patent No. 5,652,369,
30 *Amino Acid Derivatives*, issued July 29, 1997. Example substitutions are set forth in TABLE 1 as follows:

- 17 -

TABLE 1

Original residue	Example conservative substitutions
Ala (A)	Gly; Ser; Val; Leu; Ile; Pro
Arg (R)	Lys; His; Gln; Asn
Asn (N)	Gln; His; Lys; Arg
Asp (D)	Glu
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
Gly (G)	Ala; Pro
His (H)	Asn; Gln; Arg; Lys
Ile (I)	Leu; Val; Met; Ala; Phe
Leu (L)	Ile; Val; Met; Ala; Phe
Lys (K)	Arg; Gln; His; Asn
Met (M)	Leu; Tyr; Ile; Phe
Phe (F)	Met; Leu; Tyr; Val; Ile; Ala
Pro (P)	Ala; Gly
Ser (S)	Thr
Thr (T)	Ser
Trp (W)	Tyr; Phe
Tyr (Y)	Trp; Phe; Thr; Ser
Val (V)	Ile; Leu; Met; Phe; Ala

"Homology" is a measure of the *identity* of nucleotide sequences or amino acid sequences. In order to characterize the homology, subject sequences are aligned so that the highest order homology (match) is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques. Computer program methods to determine identity between two sequences, for example, include DNASTar software (DNASTar Inc., Madison, WI); the GCG program package (Devereux, J., *et al.*, Nucleic Acids Research (1984) 12(1):387); BLASTP, BLASTN, FASTA (Atschul, S. F. *et al.*, J Molec Biol (1990)

- 18 -

215:403). Homology (identity) as defined herein is determined conventionally using the well known computer program, BESTFIT (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711). When using BESTFIT or any other sequence alignment program to determine whether
5 a particular sequence is, for example, about 80% homologous to a reference sequence, according to the present invention, the parameters are set such that the percentage of identity is calculated over the full length of the reference nucleotide sequence or amino acid sequence and that gaps in homology of up to about 20% of the total number of nucleotides in the reference sequence are allowed. Eighty percent of homology is therefore determined, for
10 example, using the BESTFIT program with parameters set such that the percentage of identity is calculated over the full length of the reference sequence, e.g., SEQ ID NO:3, and gaps of up to 20% of the total number of amino acids in the reference sequence are allowed, and wherein up to 20% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 20% of the total amino acid
15 residues in the reference sequence may be inserted into the reference sequence. Percent homologies are likewise determined, for example, to identify preferred species, within the scope of the claims appended hereto, which reside within the range of about 80 percent to 100 percent homology to SEQ ID NO:3 as well as biologically and/or pharmacologically active functional derivatives thereof and biologically effective dominant negative mutants
20 contemplated herein.

Percentage *similarity* (conservative substitutions) between two polypeptides may also be scored by comparing the amino acid sequences of the two polypeptides by using programs well known in the art, including the BESTFIT program, by employing default settings for determining similarity.

25 The present invention relates, in part, to the inclusion of the polynucleotide encoding the tyrosine kinase molecule in an expression vector which can be used to transform host cells or organisms. Such transgenic hosts are useful for the production of the protein kinase as well as valuable variations thereof contemplated herein.

30 The nucleic acid sequence also provides for the design of antisense molecules, example embodiments of which are provided herein, which are useful in downregulating, diminishing, or eliminating expression, e.g., transcription and/or translation of SEQ ID NO:2 in cells.

- 19 -

The receptor tyrosine kinase molecule of the present invention is used in screening assays to identify antagonists or inhibitors which bind the kinase, emulate its substrate, or otherwise inactivate the biomolecule or compete biologically, e.g., competitive interaction or competitive binding inhibition, with the native SEQ ID NO:3 biomolecule. The tyrosine kinase
5 can also be used in screening assays to identify agonists which agonize or mimic the biological and/or pharmacological activity, induce the production of or prolong the biological half-life of the molecule *in vivo* or *in vitro*.

The invention also relates to pharmaceutical compositions which comprise molecules as depicted in SEQ ID NO:2 or SEQ ID NO:3 or variants of these molecules as defined herein for
10 the treatment of pathological disorders related to or mediated by the tyrosine kinase of the present invention.

Example Embodiments And Dominant Negative Mutants

A purified polynucleotide is preferred which comprises a nucleic acid sequence which encodes a polypeptide comprising the sequence as depicted in SEQ ID NO:3 or a variant of
15 SEQ ID NO:3, including but not limited to SEQ ID NO:3 wherein position 147 (Lysine) of SEQ ID NO:3 is substituted or deleted, SEQ ID NO:3 positions 1-25 (extracellular domain for interaction with other molecules including ligands or agonist/antagonists), SEQ ID NO:3 positions 1-122 (non-kinase domain which can be used as a dominant negative form), SEQ ID NO:3 positions 26-422 (intracellular functional domain which also can be used to make
20 chimera with other known extracellular proteins), and SEQ ID NO:3 positions 123-422 (tyrosine kinase domain which can be used for screening compounds (as well as in assay protocols)).

The tyrosine kinase (SEQ ID NO:3) coding region, SEQ ID NO:2, can be obtained from existing cDNA, for example, by PCR amplification using primers derived from SEQ ID
25 NO:1. See, e.g., Example I. SEQ ID NO:2, for example, (as well as variations thereof) may be inserted into expression vectors, with or without fusion protein "tags", for expression of a protein, e.g., SEQ ID NO:3, which can be purified and screened for biological and/or pharmacological activity, including signal transduction activity, and substrate activation. Prokaryotic expression vectors may be used including the likes of, for example, pGEX (GST
30 fusion), pET (+/- His₆ or T7 tag), as well as eukaryotic expression vectors including the likes of, for example, pcDNA3.1His, pIRES-EGFP, pcDNA3, and pEBVHis. Recombinant proteins, derived from SEQ ID NO:3, are provided for use in screening assays for the

- 20 -

identification of compounds which may modulate the biological and/or pharmacological activity of tyrosine kinases.

An example dominant negative mutant of SEQ ID NO:3 (lysine at position 147 changed to arginine) is set forth as an embodiment predicted to be catalytically inactive.

5 Antisense Molecules

Various nucleic acid sequences complementary to SEQ ID NO:1 and/or SEQ ID NO:2 provided herein may be used in another embodiment of the invention to modulate the expression of a tyrosine kinase or biological function of a downstream signal transduction molecule or transcriptional activator, including but not limited to Cdc2 kinase, by affecting the transcription and/or translation of sequences corresponding to the novel tyrosine kinase (SEQ ID NO:1 and/or SEQ ID NO:2) in cells. Pharmacological activity of the endogenous gene may be modulated by affecting the transcription and/or translation, for example, of the endogenous gene by use or administration of anti-sense constructs to produce anti-sense transcripts or by direct delivery of anti-sense oligomers. Antisense constructs and oligomers may each be used as embodiments of the present invention and each are related to therapeutic method embodiments practiced *via* direct administration as defined herein. Translation is most effectively inhibited by blocking the mRNA at a site at or near the initiation or termination codon. Thus, oligonucleotides complementary to the 5' or 3' -terminal region of the receptor tyrosine kinase mRNA transcript are preferred. Example species are provided.

Antisense molecules which comprise oligomers in the range from about 12 to about 25 nucleotides which are complementary the regions of SEQ ID NO:1 and/or 5' region pSEQ ID NO:2 which are proximal to, or include, the translational start or stop codon, or a portion thereof, are preferred embodiments of the invention. Antisense molecules comprising oligomers from about 12 to about 25 nucleotides in length which are complementary to a region within the SEQ ID NO:1 positions 67-148 or 1333-1414 are particularly preferred embodiments. Oligonucleotides which comprise sequences complementary to the following positions of SEQ ID NO:1 are example embodiments of the invention:

SEQ ID NO:1 positions 67-79; 70-82; 73-85; 75-92; 76-88; 79-91; 80-92; 81-93; 82-94; 83-95; 84-96; 85-97; 86-98; 87-99; 88-100; 89-101; 90-102; 91-103; 92-104; 93-105; 94-106; 95-107; 96-108; 97-109; 98-110; 99-111; 100-112; 101-113; 102-114; 103-115; 104-116; 105-117; 106-118; 107-119; 108-120; 109-121; 110-122; 111-123; 112-124; 113-125; 114-126; 115-127; 116-128; 117-129; 118-130; 119-131; 120-132;

- 21 -

121-133; 122-134; 123-135; 124-136; 125-137; 126-138; 127-139; 128-140; and 136-148.

SEQ ID NO:1 positions 1333-1345; 1336-1348; 1339-1351; 1342-1354; 1345-1357; 1346-1358; 1347-1359; 1348-1360; 1348-1365; 1349-1361; 1350-1362; 1351-
5 1363; 1352-1364; 1353-1365; 1354-1366; 1355-1367; 1356-1368; 1357-1369; 1358-1370; 1359-1371; 1360-1372; 1361-1373; 1362-1374; 1363-1375; 1364-1376; 1365-1377; 1366-1378; 1367-1379; 1368-1380; 1369-1381; 1370-1382; 1371-1383; 1372-1384; 1373-1385; 1374-1386; 1375-1387; 1376-1388; 1377-1389; 1378-1390; 1379-1391; 1380-1392; 1381-1393; 1382-1394; 1383-1395; 1384-1396; 1385-1397; 1386-1398;
10 1387-1399; 1388-1400; 1389-1401; 1390-1402; 1391-1403; 1392-1404; 1393-1405; 1394-1406; and 1412-1414.

Oligonucleotides which comprise sequences complementary to and hybridizable to each of the recited areas of the human receptor tyrosine kinase mRNA are contemplated for therapeutic use. Moreover, U.S. Patent No. 5,639,595, *Identification of Novel Drugs and*
15 *Reagents*, issued Jun. 17, 1997, wherein methods of identifying oligonucleotide sequences that display *in vivo* activity are thoroughly described, is herein incorporated by reference.

Nucleotide sequences that are complementary to the tyrosine kinase encoding nucleic acid sequence can be synthesized for antisense therapy. These antisense molecules may be DNA, stable derivatives of DNA such as phosphorothioates or methylphosphonates, RNA,
20 stable derivatives of RNA such as 2'-O-alkylRNA, or other oligonucleotide mimetics. U.S. Patent No. 5,652,355, *Hybrid Oligonucleotide Phosphorothioates*, issued July 29, 1997, and U.S. Patent No. 5,652,356, *Inverted Chimeric and Hybrid Oligonucleotides*, issued July 29, 1997, which describe the synthesis and effect of physiologically-stable antisense molecules, are incorporated by reference. Tyrosine kinase antisense molecules may be introduced into cells
25 by microinjection, liposome encapsulation or by expression from vectors harboring the antisense sequence. Antisense therapy may be particularly useful for the treatment of diseases where it is beneficial to modulate the effective biological and/or pharmacological activity of the tyrosine kinase presented herein.

Gene Therapy

30 Embodiments of tyrosine kinase nucleic acids or dominant negative mutant versions thereof as well as antisense embodiments described herein may be administered to a subject *via* gene therapy to modulate, i.e., boost or attenuate the corresponding biological and/or

- 22 -

pharmacological activity or gene expression of an endogenous tyrosine kinase. Nucleic acid sequences of the present invention may be delivered *ex vivo* or *in vivo* to the cells of target organs in a tissue-specific manner. The human tyrosine kinase polypeptide coding region can be ligated into viral vectors which mediate transfer of the kinase polypeptide DNA by infection of recipient host cells. Suitable viral vectors include retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, polio virus and the like. *See, e.g.*, U.S. Patent No. 5,624,820, *Episomal Expression Vector for Human Gene Therapy*, issued April 29, 1997. GENOVO Corporation, for instance, Sharon Hill, PA, at the date of this application, have a readily commercially available expression vector portfolio which comprise an assortment of vectors complete with well-established methods which consistently demonstrate tissue-specific expression. The GENOVO Corporation is an example source for vectors and methods to practice gene-therapy methods of the present invention. Nucleic acid coding regions of the present invention are incorporated into effective expression vectors, which are directly administered or introduced into somatic cells for gene therapy (a nucleic acid fragment comprising a coding region, preferably mRNA transcripts, may also be administered directly or introduced into somatic cells). *See, e.g.*, U.S. Patent No. 5,589,466, issued Dec. 31, 1996. Such nucleic acids and vectors may remain episomal or may be incorporated into the host chromosomal DNA as a provirus or portion thereof that includes the gene fusion and appropriate eukaryotic transcription and translation signals, i.e., an effectively positioned RNA polymerase promoter 5' to the transcriptional start site and ATG translation initiation codon of the gene fusion as well as termination codon(s) and transcript polyadenylation signals effectively positioned 3' to the coding region. Alternatively, the human tyrosine kinase polypeptide DNA can be transferred into cells for gene therapy by non-viral techniques including receptor-mediated targeted DNA transfer using ligand-DNA conjugates or adenovirus-ligand-DNA conjugates, lipofection membrane fusion or direct microinjection. These procedures and variations thereof are suitable for *ex vivo*, as well as *in vivo* human tyrosine kinase polypeptide gene therapy according to established methods in this art.

Generally Acceptable Vectors

In accordance with the present invention, polynucleotide sequences which encode the tyrosine kinase, fragments of the polypeptide, fusion proteins or functional equivalents thereof may be used in recombinant DNA molecules that direct the expression of the respective molecule in appropriate host cells. Due to the inherent degeneracy of the genetic code, other

DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be used to clone and express the tyrosine kinase, as well as variations thereto and dominant negative mutants thereof. As will be understood by those of skill in the art, it may be advantageous to produce nucleotide sequences possessing non-naturally occurring
5 codons.

Cloned tyrosine kinase cDNA obtained through the methods described herein may be recombinantly expressed by molecular cloning into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce the receptor kinase. Techniques for such
10 manipulations are fully described in Sambrook, J., *et al.*, Molecular Cloning Second Edition, Cold Spring Harbor Press (1990), and are well known in the art.

Expression vectors are described herein as nucleic acid sequences for the transcription of embodiments of the present invention. Such vectors can be used to express nucleic acid sequences in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells, fungal
15 cells, human, and animal cells. Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast, or bacteria-animal cells, or bacteria-fungal cells, or bacteria-invertebrate cells.

A variety of mammalian expression vectors may be used to express the recombinant human tyrosine kinase molecule as well as variants contemplated herein. Commercially
20 available mammalian expression vectors which are suitable for recombinant expression, include but are not limited to, pcDNA3 (Invitrogen), pMC1neo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pDBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCTag (ATCC 37460), and lZD35 (ATCC 37565), pLXIN and
25 pSIR (CLONTECH), pIRES-EGFP (CLONTECH). INVITROGEN corporation provides a wide variety of commercially available mammalian expression vector/systems which can be effectively used with the present invention. INVITROGEN, Carlsbad, CA. *See, also*, PHARMINGEN products, vectors and systems, San Diego, CA.

Baculoviral expression systems may also be used with the present invention to produce
30 high yields of biologically active kinase. Vectors such as the CLONETECH, BacPak™ Baculovirus expression system and protocols are preferred which are commercially available. CLONTECH, Palo Alto, CA. Miller, L.K., *et al.*, Curr. Op. Genet. Dev. 3:97 (1993);

O'Reilly, D.R., *et al.*, *Baculovirus Expression Vectors: A Laboratory Manual*, 127. Vectors such as the INVITROGEN, MaxBac™ Baculovirus expression system, insect cells, and protocols are also preferred which are commercially available. INVITROGEN, Carlsbad, CA.

Example Host Cells

5 Host cells transformed with a nucleotide sequence which encodes the signal transduction molecule of the present invention may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. Particularly preferred embodiments of the present invention are host cells transformed with a purified polynucleotide comprising a nucleic acid sequence to encode the polypeptide having the sequence as depicted
10 in SEQ ID NO:3 or a contemplated variant thereof. Cells of this type or preparations made from them may be used to screen for modulators of the biological and/or pharmacological activity of the native tyrosine kinase signal transduction molecules SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

Eukaryotic recombinant host cells are especially preferred. Examples include but are
15 not limited to yeast, mammalian cells including but not limited to cell lines of human, bovine, porcine, monkey and rodent origin, and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Cell lines derived from mammalian species which may be suitable and which are commercially available, include but are not limited to, L cells L-M(TK-) (ATCC CCL 1.3), L cells L-M (ATCC CCL 1.2), 293 (ATCC CRL 1573), Raji (ATCC CCL 86), CV-
20 1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C127I (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).

The expression vector may be introduced into host cells expressing the novel tyrosine kinase *via* any one of a number of techniques including but not limited to transformation,
25 transfection, lipofection, protoplast fusion, and electroporation. Commercially available kits applicable for use with the present invention for heterologous expression, including well-characterized vectors, transfection reagents and conditions, and cell culture materials are well-established and readily available. CLONTECH, Palo Alto, CA; INVITROGEN, Carlsbad, CA; PHARMINGEN, San Diego, CA; STRATAGENE, LaJolla, CA. The expression
30 vector-containing cells are clonally propagated and individually analyzed to determine the level of tyrosine kinase polypeptide production. Identification of host cell clones which express the novel kinase may be performed by several means, including but not limited to immunological

- 25 -

reactivity with antibodies described herein, and/or the presence of host cell-associated specific biological activity, and/or the ability to covalently cross-link specific substrate to the receptor tyrosine kinase with the bifunctional cross-linking reagent disuccinimidyl suberate or similar cross-linking reagents.

5 The signal transduction molecule of the present invention may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath, J., Protein Exp. Purif. 3:263 (1992)), protein A domains that
10 allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle WA). The inclusion of a cleavable linker sequences such as Factor XA or enterokinase (Invitrogen, San Diego CA) between the purification domain and the coding region is useful to facilitate purification.

 Systems such as the CLONTECH, TALON™ nondenaturing protein purification kit
15 for purifying 6xHis-tagged proteins under native conditions and protocols are preferred which are commercially available. CLONTECH, Palo Alto, CA.

 In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation,
20 glycosylation, phosphorylation, lipidation and acylation. Post-translational processing which cleaves a nascent form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, NIH-3T3, HEK293 etc., have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of
25 the introduced, foreign protein.

 For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express SEQ ID NO:2/SEQ ID NO:3, for example, may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the
30 introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully

- 26 -

express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type.

The signal transduction molecule, e.g., SEQ ID NO:3, can be produced in the yeast *S.cerevisiae* following the insertion of the optimal cDNA cistron into expression vectors
5 designed to direct the intracellular or extracellular expression of the heterologous protein. In the case of intracellular expression, vectors such as EmBlyex4 or the like are ligated to the beta subunit cistron. See, e.g., Rinas, U., *et al.*, *Biotechnology*, 8:543 (1990); Horowitz, B., *et al.*, *J. Biol. Chem.*, 265:4189 (1989). For extracellular expression, the kinase cistron is ligated into yeast expression vectors which may employ any of a series of well-characterized secretion
10 signals. The levels of expressed novel kinase are determined by the assays described herein.

A variety of protocols for detecting and measuring the expression of the novel molecule as well as functional derivatives thereof, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmuno assay (RIA) and fluorescent activated cell
15 sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes may be employed. Well known competitive binding techniques may also be employed. See, e.g., Hampton, R., *et al.* (1990), *Serological Methods - a Laboratory Manual*, APS Press, St Paul Minn.; Maddox, D.E., *et al.*, *J. Exp. Med.* 158:1211.

20 Screening Assays

Methods are provided to screen compounds individually or by the employment of libraries of compounds for the identification of compounds which have the ability to modulate a biological and/or pharmacological activity of a receptor tyrosine kinase, e.g., SEQ ID NO:3 described herein. The present invention is also directed to methods of screening for
25 compounds which modulate the expression (transcription and/or translation) of DNA or RNA encoding the tyrosine kinase polypeptide SEQ ID NO:3. Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non-proteinaceous organic molecules (e.g., small molecule drug compounds).

Compounds may modulate an ultimate biological and/or pharmacological activity by
30 increasing or attenuating the expression of DNA or RNA encoding the human signal-transduction biomolecule or a function of the native SEQ ID NO:3. Compounds that modulate the expression of DNA or RNA encoding the tyrosine kinase polypeptide or the function of the

- 27 -

polypeptide may be detected by a variety of assays. The assay may be a simple "yes/no" assay to determine whether there is a change in expression or function. The assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample.

5 The human receptor tyrosine kinase described herein, SEQ ID NO:3, its functional fragments or oligopeptides including but not limited to SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-422, as well as variants contemplated herein can be used for screening prospective therapeutic compounds in any of a variety of drug screening techniques. The fragment or entity employed
10 in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition or modulation of activity or the formation of binding complexes, between the human signal-transduction kinase and the agent being tested, may be measured, for example, by means provided.

 It is expected that the novel human signal transduction receptor tyrosine kinase will
15 have high catalytic activity that will permit easy adaptation to automated high throughput screening assays, including scintillation proximity assays, which are well known in the art. See, e.g., U.S. Patent No. 5,763,198, *Screening Assays for Compounds*, issued June 9, 1998 (an example rapid, quantitative, specific, high through-put assay systems for screening test compounds such as drugs, ligands (natural or synthetic), ligand antagonists, peptides, or small
20 organic molecules *for their ability to modulate tyrosine kinase activity* within the cell or in a cell-free system); U.S. Patent No. 5,763,584, *Receptor Activation with Hepatocyte Growth Factor Agonists*, issued June 9, 1998 (an example method for activating receptors selected from *receptor tyrosine kinases* and for making ligand variants that act as competitive agonists of the respective native ligands); and, U.S. Patent No. 5,763,441, *Compounds for the*
25 *Treatment of Disorders Related to Vasculogenesis and/or Angiogenesis*, issued June 9, 1998, which are herein incorporated by reference as examples. Moreover, Scintillation Proximity Assay (SPA) technology is set forth as an embodiment which allows rapid and sensitive assay of a wide variety of molecular interactions in a homogeneous system (AMERSHAM, Bucks, UK).

30 Accordingly, the present invention provides a method for screening a plurality of compounds for specific binding affinity with the native polypeptide SEQ ID NO:3 or a variant thereof contemplated herein, comprising providing a plurality of compounds; combining an

embodiment of the tyrosine kinase of the present invention with each of a plurality of compounds for a time sufficient to allow binding under suitable conditions; and detecting binding of the kinase polypeptide, or fragment thereof, to each of the plurality of compounds, thereby identifying the compounds which specifically bind the signal-transduction kinase polypeptide.

Methods of identifying compounds that modulate a biological and/or pharmacological activity of a signal transduction molecule are generally preferred, which comprise combining a candidate compound modulator of signal transduction activity (biological and/or pharmacological) with a polypeptide having the sequence as depicted in SEQ ID NO:3 or a variant thereof contemplated herein, and measuring an effect of the candidate compound modulator on the biological and/or pharmacological activity of the polypeptide. The kinase activity of the biomolecule may be assayed and/or to the performance of any one or more of the functions including but not limited to the ability to autophosphorylate, to phosphorylate a substrate, to bind ATP, and to mediate the activation of Cdc2 kinase. The pharmacological activity of the biomolecule may be assayed by means of comparing, to control cells, for example, the manifestation and rate of mitosis, cell differentiation, proliferation, oncogenic transformation, neoplasia, cell aggregation, and cytokinesis.

Assays for the novel receptor tyrosine kinase, kinase activity, are performed via well known ser/thr kinase assays, except MBP is substituted with enolase. Cooper, *et al.*, J. Biol. Chem., 259:7835 (1984). Phosphorylation sites in enolase are utilized by tyrosine protein kinases *in vivo* and *in vitro*. See, Examples V and VI.

The ability of the receptor tyrosine kinase to phosphorylate a substrate and/or bind a cognate ligand may be measured by methods well-known to those skilled in the art. See, e.g., U.S. Patent No. 5,763,584, *Receptor Activation with Hepatocyte Growth Factor Agonists*, issued June 9, 1998 (an example method for activating receptors selected from receptor tyrosine kinases and for making ligand variants that act as competitive agonists of the respective native ligands); U.S. Patent No. 5,763,198, *Screening Assays for Compounds*, issued June 9, 1998 (an example rapid, quantitative, specific, high through-put assay systems for screening test compounds such as drugs, ligands (natural or synthetic), ligand antagonists, peptides, or small organic molecules for their ability to modulate tyrosine kinase activity within the cell or in a cell-free system); and, U.S. Patent No. 5,763,441, *Compounds for the*

Treatment of Disorders Related to Vasculogenesis and/or Angiogenesis, issued June 9, 1998, which are herein incorporated by reference as examples.

Biological activity as used herein in reference to the tyrosine kinase of the present invention refers to *inter alia* mediation of activation of Cdc2 kinase which mediates mitosis.

- 5 See, e.g., Nishio K., *et al.*, *Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines*, Anticancer Research, 16(6B):3387 (1996); Vincent I., *et al.*, *Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain*, Journal of Neuroscience, 17(10):3588 (1997).

- Accordingly, methods of identifying compounds that modulate a biological and/or
10 pharmacological activity of a tyrosine kinase are particularly preferred which comprise combining a candidate compound modulator with a host-cell expressing a polypeptide having the sequence as depicted in SEQ ID NO:3 or a variant thereof contemplated herein and measuring an effect of the candidate compound modulator on the biological and/or pharmacological activity of the polypeptide. Preferred cellular assays for modulators of the
15 subject tyrosine kinase signal transduction molecule fall into two general categories: 1) direct measurement of a biological activity, and 2) measurement of downstream events in the signaling cascade including cell/tissue/organism physiological manifestations.

- In order to measure activity of the tyrosine kinase, the source of the molecule to be assayed may be a whole cell lysate, prepared by one to three freeze-thaw cycles in the presence
20 of standard protease inhibitors. Alternatively, the kinase may be partially or completely purified by standard protein purification methods. The kinase may be purified by affinity chromatography using antibodies described herein or by ligands specific for the epitope tag engineered into the recombinant kinase moreover described herein. The preparation may then be assayed for activity. Example assays used to screen for compounds which modulate kinase
25 activity, for example, are set forth *infra*. See, e.g., Examples V and VI.

- In another method embodiment of the invention to identify agents which modulate a biological activity of the novel biomolecule set forth herein, a nucleic acid sequence which encodes a signal-transduction molecule, for example as depicted in SEQ ID NO:3, may be ligated to a heterologous sequence to encode a fusion protein for use in a yeast 2-hybrid
30 system. To screen compounds for the modulation of SEQ ID NO:3 biological activity, it is necessary to encode a chimeric peptide for expression in heterologous host cells. Chimeric constructs are also used to express a 'bait', according to methods well known using a yeast

- 30 -

two-hybrid system, using accessory native peptides that are expected to be associated with the tyrosine kinase molecule described herein. The two-hybrid system uses the ability of a pair of interacting proteins to bring a transcription activation domain into close proximity with a DNA-binding site that regulates the expression of an adjacent reporter gene. Compounds
5 which are able to modulate the biological activity of the novel biomolecule as defined herein are identified by their ability to effect protein:protein interactions (reconstitution of the chimeric transcriptional activators) and hence the yeast 2-hybrid readout assays well-known to artisans of ordinary skill in this area of molecular biology. Fields, S., *et al.*, Trends Genet., 10:286 (1994); Allen, J.B., *et al.*, TIBS, 20:511 (1995). Fields, S., Song, O., Nature 340:245
10 (1989). Commercially available systems such as the CLONTECH, Matchmaker™ systems and protocols may be used with the present invention. CLONTECH, Palo Alto, CA. See also, Mendelsohn, A.R., Brent, R., Curr. Op. Biotech., 5:482 (1994); Phizicky, E.M., Fields, S., Microbiological Rev., 59(1):94 (1995); Yang, M., *et al.*, Nucleic Acids Res., 23(7):1152 (1995); Fields, S., Sternglanz, R., TIG, 10(8):286 (1994); and US Patents 5,283,173, *System*
15 *to Detect Protein-Protein Interactions*, and 5,468,614, which are incorporated herein by reference.

To further evaluate the ability of a compound to modulate the pharmacological activity, for example, of SEQ ID NO:3, human tumor cells are injected into SCID mice (severe combined immunodeficiency) to form palpable tumor masses. See, Example VII.

20 Compounds which are identified generally according to methods described, contemplated, and referenced herein that modulate a biological and/or pharmacological activity of a human receptor tyrosine kinase of the sequence as depicted in SEQ ID NO:3 are especially preferred embodiments of the present invention.

An especially preferred embodiment of the present invention is a method for treatment
25 of a patient in need of such treatment for a condition which is mediated by the tyrosine kinase molecule described herein, e.g., SEQ ID NO:3, comprising administration of a therapeutically effective amount of a modulating compound identified using sequences as depicted in SEQ ID NO:1, SEQ ID NO:2 and/or SEQ ID NO:3 or a contemplated variant thereof as a pharmacological target in methods contemplated herein.

30 A method of modulating a biological and/or pharmacological activity of a signal transduction kinase in a cell, tissue, or organism is preferred which comprises administering an effective amount of a polynucleotide contemplated herein. 'Polynucleotide' includes a

- 31 -

polynucleotide comprising a nucleic acid sequence which encodes a polypeptide having at least about 80% homology to SEQ ID NO:3, SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-422; as well as a polynucleotide comprising a nucleic acid sequence which encodes a polypeptide comprising the sequence as depicted in SEQ ID NO:3 wherein position 147 (Lysine) of SEQ ID NO:3 is substituted or deleted; as well as antisense molecules which are complementary to a region within SEQ ID NO:1 positions 67-148 or 1333-1414, example therapeutic embodiments of which are set forth *supra*.

Antibodies

10 The receptor tyrosine kinase can be used to raise diagnostic antibodies as to detect abnormal levels of the biomolecule *in vivo*. Therefore, in accordance with yet a further aspect of the present invention, there are provided antibodies against the receptor tyrosine kinase polypeptide which may used as part of various diagnostic assays for detecting physiological disorders including cancer tissue. An example for the production of effective polyclonal antibodies against peptides derived from SEQ ID NO:3, for employment in methods described herein, is EADRPSPRELRLRL (SEQ ID NO:4) which was identified within the c-terminal region of the novel human tyrosine kinase (SEQ ID NO:3) utilizing a well established algorithm method developed by Jameson and Wolf. *The antigenic Index: A novel Algorithm for Predicting Antigenic Determinants*, CABIOS, 4:181 (1988). This peptide was conjugated to keyhole limpet hemocyanin and used for antibody generation by GENOSYS BIOTECHNOLOGIES, 1442 Lake Front Circle, Suite 185, The Woodlands, Texas 77380. Specific antibodies may be raised by immunizing animals, with rabbits being preferred, with an appropriate concentration of the human tyrosine kinase either with or without an immune adjuvant.

25 Monospecific antibodies to the polypeptide of the present invention are purified from mammalian antisera containing antibodies reactive against the polypeptide or are prepared as monoclonal antibodies reactive with the signal transduction polypeptide using the technique of Kohler and Milstein, *Nature*, 256:495 (1975). Mono-specific antibody as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for the novel signal transduction molecule. Homogenous binding as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with SEQ ID NO:3. Monoclonal antibodies are produced *in vivo* by injection

30

of pristane primed Balb/c mice, approximately 0.5 ml per mouse, with about 2×10^6 to about 6×10^6 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art. *In vitro* production of the anti-polypeptide mAb is carried out by growing the
5 hybridoma in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

Purification Of SEQ ID NO:3 Via Affinity Columns

It is readily apparent to those skilled in the art that methods for producing antibodies may be utilized to produce antibodies specific for the tyrosine kinase polypeptide fragments, or
10 the full-length nascent polypeptide, e.g., SEQ ID NO:3. Specifically, it is readily apparent to those skilled in the art that antibodies may be generated which are specific for the fully functional protein and fragments and variants thereof.

Tyrosine kinase polypeptide antibody affinity columns are made by adding the antibodies to Affigel-10 (Biorad), a gel support which is activated with N hydroxysuccinimide
15 esters such that the antibodies form covalent linkages with the agarose gel bead support. The antibodies are then coupled to the gel via amide bonds with the spacer arm. The remaining activated esters are then quenched with 1M ethanolamine HCl (pH 8). The column is washed with water followed by 0.23M glycine HCl (pH 2.6) to remove any non-conjugated antibody or extraneous protein. The column is then equilibrated in phosphate buffered saline (pH 7.3)
20 with appropriate detergent and the cell culture supernatants or cell extracts containing human tyrosine kinase polypeptide made using appropriate membrane solubilizing detergents are slowly passed through the column. The column is then washed with phosphate buffered saline/detergent until the optical density falls to background, then the protein is eluted with 0.23M glycine-HCl (pH 2.6)/detergent. The purified polypeptide is then dialyzed against
25 phosphate buffered saline/detergent.

Recombinant tyrosine kinase molecules can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full length nascent signal transduction polypeptide, or polypeptide fragments.

Polypeptides described herein may be used to affinity purify biological effectors from
30 native biological materials, e.g. disease tissue. Affinity chromatography techniques are well known to those skilled in the art. A tyrosine kinase peptide described herein or an effective fragment thereof, is fixed to a solid matrix, e.g. CNBr activated Sepharose according to the

protocol of the supplier (Pharmacia, Piscataway, NJ), and a homogenized/buffered cellular solution containing a potential molecule of interest is passed through the column. After washing, the column retains only the biological effector which is subsequently eluted, e.g., using 0.5M acetic acid or a NaCl gradient.

5 Diagnostic Assays

Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar diagnostic assays are used to detect the presence
10 of the novel signal transduction kinase polypeptide in body fluids or tissue and cell extracts.

Diagnostic assays using the human signal-transduction polypeptide specific antibodies are useful for the diagnosis of conditions, disorders or diseases characterized by abnormal expression of the receptor tyrosine kinase or expression of genes associated with abnormal cell growth. Diagnostic assays for the signal-transduction kinase of this invention include methods
15 utilizing the antibody and a label to detect the human kinase polypeptide in human body fluids, cells, tissues or sections or extracts of such tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule, a myriad of which are well-known to those skilled in the art.

20 A variety of protocols for measuring the kinase polypeptide, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on the human signal-
25 transduction kinase polypeptide is preferred, but a competitive binding assay may be employed. These assays are described, among other places, in Maddox, D.E. *et al.*, J. Exp. Med. 158:1211 (1983); Sites, D.P., *et al.*, *Basic and Clinical Immunology*, Ch.22, 4th Ed., Lange Medical Publications, Los Altos, CA (1982); U.S. Patents No. 3,654,090, No. 3,850,752; and No. 4,016,043.

30 In order to provide a basis for the diagnosis of disease, normal or standard values for the tyrosine kinase, normal expression levels must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with

- 34 -

antibody to the human kinase polypeptide under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing it with a dilution series of positive controls where a known amount of antibody is combined with known concentrations of purified tyrosine kinase polypeptide.

- 5 Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by a disorder or disease related to the human tyrosine kinase expression. Deviation between standard and subject values establishes the presence of the disease state.

- Kits containing a corresponding tyrosine kinase nucleic acid or antibodies to a
10 corresponding polypeptide, or protein, e.g., SEQ ID NO:3 may be prepared. Such kits are used to detect heterologous nucleic acid which hybridizes to the nucleic acid or may be amplified via PCR, or to detect the presence of protein or peptide fragments in a sample. Such characterization is useful for a variety of purposes including, but not limited to, diagnosis of pathophysiological conditions, forensic analyses, and epidemiological studies.

- 15 The DNA molecules, RNA molecules, recombinant protein and antibodies of the present invention may be used to screen and measure levels of the novel kinase DNA, RNA or protein. The recombinant proteins, DNA molecules, RNA molecules and antibodies lend themselves to the formulation of kits suitable for the detection and typing of the signal-transduction tyrosine kinase. Such a kit comprises a compartmentalized carrier suitable to hold
20 in close confinement at least one container. The carrier would further comprise reagents such as recombinant kinase or anti-kinase antibodies suitable for detecting the novel molecule as depicted in SEQ ID NO:3. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

- Polynucleotide sequences which encode the transduction molecule may be used for the
25 diagnosis of conditions or diseases with which the expression of the novel human stress-activated kinase is associated. For example, polynucleotide sequences encoding the signal-transduction molecule may be used in hybridization or PCR assays of fluids or tissues from biopsies to detect expression of the kinase. The form of such qualitative or quantitative methods may include Southern or northern analysis, dot blot or other membrane-based
30 technologies; PCR technologies; dip stick, pin, chip and ELISA technologies. All of these techniques are well known in the art and are the basis of many commercially available diagnostic kits. Such assays may also be used to evaluate the efficacy of a particular

- 35 -

therapeutic treatment regime in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. Once disease is established, a therapeutic agent is administered and a treatment profile is generated. Such assays may be repeated on a regular basis to evaluate whether the values in the profile progress toward or return to the normal or standard pattern.

- 5 Successive treatment profiles may be used to show the efficacy of treatment over a period of several days or several months.

Polynucleotide sequences which encode the novel kinase may also be employed in analyses to map chromosomal locations, e.g., screening for functional association with disease markers. Moreover the sequences described herein are contemplated for use to identify human
10 sequence polymorphisms and possible association with disease as well as analyses to select optimal sequence from among possible polymorphic sequences for the design of compounds to modulate the biological and/or pharmacological activity. Furthermore the sequences are contemplated as screening tools for use in the identification of appropriate human subjects and patients for therapeutic clinical trials.

15 **PCR Diagnostics**

The nucleic acid sequence, oligonucleotides, fragments, portions or antisense molecules thereof, may be used in diagnostic assays of body fluids or biopsied tissues to detect the expression level of the novel human signal-transduction kinase molecule. For example, sequences designed from the cDNA sequence SEQ ID NO:1 or sequences comprised in SEQ
20 ID NO:2 can be used to detect the presence of the mRNA transcripts in a patient or to monitor the modulation of transcripts during treatment. Several examples of PCR primers derived from SEQ ID NO:1 are set forth herein.

Diagnostic or compositions for pharmacogenomic analysis are preferred for the identification of a polynucleotide sequence comprising PCR primers derived from SEQ ID
25 NO:1 or allele sequences described herein representative of 11, 12, 13 or 15 GT repeats between positions 2125 and 2152 of SEQ ID NO:1.

One method for amplification of target nucleic acids, or for later analysis by hybridization assays, is known as the polymerase chain reaction ("PCR") or PCR technique. The PCR technique can be applied to detect sequences of the invention in suspected samples
30 using oligonucleotide primers spaced apart from each other and based on the genetic sequence, e.g., SEQ ID NO:1, set forth herein. The primers are complementary to opposite strands of a double stranded DNA molecule and are typically separated by from about 50 to 450

- 36 -

nucleotides or more (usually not more than 2000 nucleotides). This method entails preparing the specific oligonucleotide primers followed by repeated cycles of target DNA denaturation, primer binding, and extension with a DNA polymerase to obtain DNA fragments of the expected length based on the primer spacing. One example embodiment of the present invention is a diagnostic composition for the identification of a polynucleotide sequence comprising the sequence as depicted in SEQ ID NO:2 comprising PCR primers derived from SEQ ID NO:1. The degree of amplification of a target sequence is controlled by the number of cycles that are performed and is theoretically calculated by the simple formula 2^n where n is the number of cycles. See, e.g., Perkin Elmer, *PCR Bibliography*, Roche Molecular Systems, Branchburg, New Jersey; CLONTECH products, Palo Alto, CA; U.S. Patent No. 5,629,158, *Solid Phase Diagnosis of Medical Conditions*, issued May 13, 1997.

Compositions

Pharmaceutically useful therapeutic compositions which comprise a nucleic acid coding region, a dominant negative mutant coding region, an antisense molecule described herein, a polypeptide as depicted in SEQ ID NO:3 or a variation thereof contemplated herein, or a compound that modulates the biological and/or pharmacological activity of the signal transduction biomolecule set forth herein may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in *Remington's Pharmaceutical Sciences* (Maack Publishing Co, Easton, PA). To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, or modulator.

Therapeutic or diagnostic compositions of the invention are administered to an individual or used in amounts sufficient to treat or diagnose disorders related to or mediated by the receptor tyrosine kinase described herein. The effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.

The term functional derivative includes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base

molecule. Examples of such moieties are described in a variety of texts, such as *Remington's Pharmaceutical Sciences*.

Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. The therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. A therapeutically effective dose refers to that amount of compound, protein, peptide, nucleic acid, antibodies, antagonists, or inhibitors which ameliorate the symptoms or condition. The exact dosage is chosen by the individual physician in view of the patient to be treated.

Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages defined by routine testing in order to obtain optimal modulation of a signal-transduction tyrosine kinase, or its activity while minimizing any potential toxicity. In addition, co-administration or sequential administration of other agents may be desirable.

The pharmaceutical compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular. Administration of pharmaceutical compositions is accomplished orally or parenterally. Methods of parenteral delivery include topical, intra-arterial (directly to the tissue), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration. The present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention. The compositions containing compounds identified according to this invention as the active ingredient for use in the modulation of a signal-transduction molecule can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration. For example, the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection. Likewise, they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all

using forms well known to those of ordinary skill in the pharmaceutical arts. An effective but non-toxic amount of the compound desired can be employed as a signal-transduction tyrosine kinase modulating agent.

The daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult human/per day. For oral administration, the compositions are preferably provided in the form of scored or unscored tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, and 50.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.0001 mg/kg to about 100 mg/kg of body weight per day. The range is more particularly from about 0.001 mg/kg to 10 mg/kg of body weight per day. Even more particularly, the range varies from about 0.05 to about 1 mg/kg. Of course the dosage level will vary depending upon the potency of the particular compound. Certain compounds will be more potent than others. In addition, the dosage level will vary depending upon the bioavailability of the compound. The more bioavailable and potent the compound, the less compound will need to be administered through any delivery route, including but not limited to oral delivery. The dosages of the human signal-transduction kinase modulators are adjusted when combined to achieve desired effects. On the other hand, dosages of these various agents may be independently optimized and combined to achieve a synergistic result wherein the pathology is reduced more than it would be if either agent were used alone. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells and conditions.

Examples

Example I Production and purification of GST-fusion protein containing the novel human signal transduction tyrosine kinase polypeptide

The cDNA (SEQ ID NO:1) which encodes the novel human signal transduction tyrosine kinase (SEQ ID NO:3) may be produced using the primers:

1. 5'- GCCGTCGACTGTGGGCCTAGCAGGGAA -3' (SEQ ID NO:5)
2. 5'- GCCGCGGCCGCTCAAAGCATGCTATAG -3' (SEQ ID NO:6)

The PCR product is cloned into the Sal I and Not I restriction enzyme sites in the pGEX-5X-3 vector (PHARMACIA BIOTECH, Piscataway, NJ).

- 39 -

A single colony of DH5alpha (LIFE TECHNOLOGIES, Gaithersburg, MD) expressing GST fused to the novel tyrosine kinase with and without the transmembrane region is inoculated in 10 ml of LB/amp (100µg/ml) for overnight culture with a rotation of 275 rpm at 37° C. Next day, the O/N culture is diluted to 100ml in LB/amp and grown for an hour. IPTG is added to 5 0.5 mM and grown for additional 3 hrs. The rest of the steps are done at 4° C. Bacteria is harvested by spinning at 5000 rpm for 5 min and re-suspended in 15 ml lysis buffer containing 50mM Tris (pH 8.0), 150mM NaCl, 0.5% Triton X-100, 1mM PMSF and Complete Protease Inhibitor Cocktail. Cells are lysed by sonicating on ice. The lysed cells are centrifuged and the supernatant containing fusion proteins is collected. The GST-fusion protein is purified 10 using 150 µl of packed beads of Glutathione-Sepharose 4B beads. Beads are incubated with cell lysate for 1 hr and the beads are washed 5x with 50mM Tris (pH 8.0), 150mM NaCl, 0.1% Triton X-100, 1mM PMSF and Complete Protease Inhibitor Cocktail. The washed beads are kept at 4° C, as a 2% suspension in the same buffer with 0.02% azide.

Example II

15 **Demonstration of a variable number of GT repeats in the tyrosine kinase gene**

To determine allele frequency of the tyrosine kinase in humans, positions 2062-2083 of SEQ ID NO:1 (forward primer) and positions 2239-2250 of SEQ ID NO:1 (reverse primer) were used in PCR amplification of this fragment of genomic DNA from 27 unrelated Caucasians. The reverse oligo was modified to include the M13F sequence (Vieira, J. and 20 Messing, J., *Methods in Enzymol.*, 153:3 (1987)) at its 5'end. The PCR products were sequenced by dye-primer sequencing (Martin, *et al.*, *Bio/Technology*, 3:911 (1985) using an M13F primer.

The number of CA/GT repeats between positions 2125 and 2152 corresponding to SEQ ID NO:1 were counted. SEQ ID NO:1 as listed herein demonstrates a total of 14 GT 25 repeat sequences between positions 2125 and 2152. DNA sequencing of the PCR fragments showed 11,12,13,14 and 15 copies of the GT repeat in the genomic DNA of the Novel tyrosine kinase gene from 27 caucasians with the following frequencies:

- 40 -

Allele Frequency

	11	6/54
	12	2/54
	13	17/54
5	14	16/54
	15	13/54

No homozygotes were observed for any allele. Each of the alleles are intended to be within the scope of the claims appended hereto (SEQ ID NO:1).

10 Example III**Antisense Oligonucleotides Derived From SEQ ID NO:1 Inhibit Proliferation Of A549 Cells**

Oligonucleotides are added to A549 cells at 2 μ M concentration using the following experimental conditions. A549 cells are seeded at a concentration of 3000 cells per well in a 96 well culture plate. The cells are incubated overnight before transfection. The medium is aspirated, and the cells are washed once with 150 μ l Opti-MEM. Subsequently, 70 μ l Opti-MEM containing 30 μ l Lipofectin/ml Opti-MEM per 2 μ M oligo is used. The cells are incubated with the selected oligomer for 3-6 hours at 37°C with 5% CO₂. After that incubation 70 μ l complete medium containing 2X FBS is added into each well. Cell proliferation is measured 20 hours after transfection using One Solution Cell Proliferation Assay Kit from Promega. Briefly, 28 μ l of One Solution Reagent is added into each well and the plates are incubated for 2 hours at 37°C in a humidified, 5% CO₂ atmosphere. After the 2 h incubation, the absorbance is measured at 490 nm.

Example IV**25 Immunoprecipitation**

Experiments demonstrate the presence of the novel human signal transduction tyrosine kinase. Human lung carcinoma cell line (A549) was lysed in lysis buffer containing 50mM Tris (pH8.0), 150mM NaCl, 0.5% Triton X-100, 1mM PMSF and Complete Protease Inhibitor Cocktail. All the steps were carried at 4⁰ C. Cell lysates from approximately 2.5X10⁶ lung carcinoma cells were incubated with 10 μ l of rabbit polyclonal antiserum for 2 hrs. with continuous rotation. Preimmune serum from the same rabbit was used as a negative control.

Immune complexes were captured by the addition of Protein A Sepharose beads (Pharmacia) and rocking for additional 1 hr. The beads were washed 5 times in lysis buffer. The bound protein was eluted in sample buffer and subjected to SDS-PAGE on a 8% gel.

Example V

5 Assay For Kinase Activity

Recombinant, purified GST/SEQ ID NO:3 kinase (or other recombinant protein derived from SEQ ID NO:3) is added to 20 μ g enolase in 10 μ L of a 3X kinase reaction buffer (KRB) containing (in mM): 60 HEPES (pH 7.5), 30 magnesium acetate, 0.15 ATP, 3 DTT, 0.03 sodium orthovanadate. The reaction is started by the addition of 5 μ Ci [γ -³²P] ATP
10 (10 μ L). Samples are incubated for 5 minutes at 30°C. The reaction stopped by addition of 4X Laemmli sample buffer. Proteins are separated on 12% Tris/glycine SDS gels, stained with Coomassie blue, dried and exposed to autoradiograph film.

Example VI

High Throughput Screening For Compounds Which Modulate Activity

15 High throughput screening for modulator compounds is performed using enolase coated 96-well FlashPlates® (NEN™ Life Science Products). Kinase reaction buffer (3X kinase reaction buffer (KRB) contains: 60 mM HEPES (pH 7.5), 30 mM magnesium acetate, 0.15 mM ATP, 3 mM DTT, 0.03 mM sodium orthovanadate) 0.25 μ Ci [γ ³³P]-ATP at a concentration no greater than 1 μ g/ml, (determined by titration of individual enzyme
20 preparations for a concentration that allows kinetic determinations over a 1 hour time course of the tyrosine kinase) are added to each well and incubated 1 hour at 30°C in the presence or absence of 10 μ M test compound. Total reaction volume is 100 μ L. Following incubation, the reaction mixture is aspirated and the wells rinsed 2 times with 300 μ L PBS. Incorporation of radiolabeled phosphate is determined by scintillation counting, Packard Instrument Co. Top
25 Count, 12-detector, 96-well microplate scintillation counter and luminescence counter, model B991200. Compounds which inhibit kinase activity \geq 50 percent at 10 μ M are indicated by a >50% reduction in scintillation counts. Specificity and selectivity are determined by titration of inhibitory compounds to determine the IC₅₀ (or other standard quantitation well known in the art for comparison) and by the substitution of other kinases in the assay. For example,
30 determination of relative inhibitory activity of kinases in comparison to recombinant SEQ ID NO:3 expressed and isolated in a similar manner, assayed under similar conditions, provides

selectivity data. Cooper, *et al.*, J. Biol. Chem., 259:7835 (1984). Phosphorylation sites in enolase are utilized by tyrosine protein kinases *in vivo* and *in vitro*.

Alternatively, a filter assay may be used. This protocol is the same but the reaction is stopped by the addition of EDTA (pH 7.0) to a final concentration of 80mM. Samples are
5 then centrifuged and 50 μ L of the supernatant spotted on p81 cation-exchange filter paper (Whatman, No. 3698 915). The filters are then washed 3 times in 200mL of 180mM H₃PO₄ (5-10min each) and once in 200mL of 96% ethanol. After air drying the filters, radioactivity is determined by Cerenkov counting in a scintillation counter.

Example VII

10 Efficacy In Vivo (Pharmacological Activity) Screen

To further evaluate the ability of a compound to inhibit human tumor growth, for example, human tumor cells are injected into SCID mice (severe combined immunodeficiency) to form palpable tumor masses. The effects of various doses (e.g., 0.5-50mg) of a compound in inhibiting tumor growth can be determined as follows: approximately 1×10^7 cells of the
15 CCL 221 cell line (ATCC, Rockville, Md.), a human colon adenocarcinoma cell line, is suspended in 100 μ L DMEM and injected subcutaneously into SCID mice, such that two tumors per mouse are formed. SCID mice receive CCL 221 cells and the tumors are grown for 7 days without treatment; on the 7th day (Day 0) tumor maximal diameters and animal weights are recorded and the mean tumor size for the mice is determined. On Day 1 (eight
20 days following tumor cell injection), treatment of the mice with the candidate compound or vehicle alone is begun. One group of the mice (controls) are injected intraperitoneally with 0.2 ml of vehicle and a second group of mice receives compound by intraperitoneal injection. Various doses (0.25-75mg) of the compound can be tested in separate groups of mice. On Day 7 and Day 14, animal weight and maximal tumor diameter is measured. Average maximal
25 tumor size for each group on Day 0, Day 7, and Day 14 are compared Day 14, one high dose animal is followed for an additional to determine whether the agent produces a dose-dependent inhibition of tumor growth. Toxicity effects can be examined by tracking mice weight and by harvesting lungs, livers, and spleens of the animals for histological staining.

* * *

30 All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the

- 43 -

scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in

5 molecular biology or related fields are intended to be within the scope of the following claims.

CLAIMS:

What is claimed is:

1. A purified polynucleotide comprising a nucleic acid sequence which encodes a polypeptide having at least about 80% homology to a member selected from the group consisting essentially of: (SEQ ID NO:3, SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-422).
2. A polynucleotide according to Claim 1 comprising a nucleic acid sequence which encodes a polypeptide comprising the sequence as depicted in SEQ ID NO:3.
3. A polynucleotide according to Claim 1 comprising a nucleic acid sequence which encodes a polypeptide comprising the sequence as depicted in SEQ ID NO:3 wherein position 147 (Lysine) of SEQ ID NO:3 is substituted or deleted.
4. A polynucleotide according to Claim 3 comprising a nucleic acid sequence which encodes a polypeptide comprising the sequence as depicted in SEQ ID NO:3 wherein position 147 of SEQ ID NO:3 is Arginine.
5. A polynucleotide according to Claim 1 comprising a nucleic acid sequence which encodes a polypeptide comprising a sequence selected from the group consisting essentially of: (SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-422).
6. A polynucleotide of Claim 2 wherein the polynucleotide sequence comprises the sequence as depicted in SEQ ID NO:2.
7. An antisense molecule comprising an oligomer in the range from about 12 to about 25 nucleotides in length which: (a) is complementary to a region within positions 67-148 of SEQ ID NO:1; or, (b) comprises a sequence which is complementary to a sequence selected from the group consisting of: (SEQ ID NO:1 positions 67-79; 70-82; 73-85; 75-92; 76-88; 79-91; 80-92; 81-93; 82-94; 83-95; 84-96; 85-97; 86-98; 87-99; 88-100; 89-101; 90-102; 91-103; 92-104; 93-105; 94-106; 95-107; 96-108; 97-109; 98-110; 99-111; 100-112;

- 45 -

101-113; 102-114; 103-115; 104-116; 105-117; 106-118; 107-119; 108-120; 109- 121;
110-122; 111-123; 112-124; 113-125; 114-126; 115-127; 116-128; 117-129; 118-130;
119-131; 120-132; 121-133; 122-134; 123-135; 124-136; 125-137; 126-138; 127-139;
128-140; and 136-148).

5

8. An antisense molecule comprising an oligomer in the range from about 12 to about 25 nucleotides in length which: (a) is complementary to a region within positions 1333-1414 of SEQ ID NO:1; or, (b) comprises a sequence which is complementary to a sequence selected from the group consisting of: (SEQ ID NO:1 positions 1333-1345; 1336-1348; 1339-1351;
10 1342-1354; 1345-1357; 1346-1358; 1347-1359; 1348-1360; 1348-1365; 1349- 1361;
1350-1362; 1351-1363; 1352-1364; 1353-1365; 1354-1366; 1355-1367; 1356-1368; 1357-
1369; 1358-1370; 1359-1371; 1360-1372; 1361-1373; 1362-1374; 1363-1375; 1364-
1376; 1365-1377; 1366-1378; 1367-1379; 1368-1380; 1369-1381; 1370-1382; 1371-
1383; 1372-1384; 1373-1385; 1374-1386; 1375-1387; 1376-1388; 1377-1389; 1378-
15 1390; 1379-1391; 1380-1392; 1381-1393; 1382-1394; 1383-1395; 1384-1396; 1385-
1397; 1386-1398; 1387-1399; 1388-1400; 1389-1401; 1390-1402; 1391-1403; 1392-
1404; 1393-1405; 1394-1406; and 1412-1414).

9. An expression vector comprising the polynucleotide of Claim 1.

20

10. A host cell transformed with the expression vector of Claim 9.

11. A purified polypeptide comprising the amino acid sequence as depicted in SEQ ID NO:3 or a variant of SEQ ID NO:3 having at least about 80% homology to a member selected
25 from the group consisting essentially of: (SEQ ID NO:3, SEQ ID NO:3 positions 1-25, SEQ ID NO:3 positions 1-122, SEQ ID NO:3 positions 26-422, and SEQ ID NO:3 positions 123-422).

12. An antibody specific for the polypeptide SEQ ID NO:3.

30

- 46 -

13. A method for producing a polypeptide according to Claim 11, said method comprising the steps of:

a) culturing a host cell according to Claim 10 under conditions suitable for the expression of said polypeptide, and

5 b) recovering said polypeptide from the host cell culture.

14. A method of identifying compounds that modulate a biological and/or pharmacological activity of a tyrosine kinase, comprising:

(a) combining a candidate compound modulator with a polypeptide according to Claim 10 11, and measuring an effect of the candidate compound modulator on the biological and/or pharmacological activity of the polypeptide.

15. A method of identifying compounds that modulate a biological and/or pharmacological activity of a tyrosine kinase according to Claim 14, comprising:

15 combining a candidate compound modulator with a host-cell which expresses said polypeptide, and measuring an effect of the candidate compound modulator on the biological and/or pharmacological activity of the polypeptide.

16. A compound that modulates the activity of a tyrosine kinase identified by the method of Claim 14.
20

17. A method of treatment of a patient in need of such treatment for a condition which is mediated by a tyrosine kinase, comprising administering an effective amount of a compound according to Claim 16.

25

18. A method of modulating a biological and/or pharmacological activity of a tyrosine kinase in a cell comprising administering an effective amount of a polynucleotide according to Claim 1 to said cell.

30 19. A method for modulating the expression of a tyrosine kinase in a cell comprising administering an effective amount of an antisense molecule according to Claim 7 or Claim 8 to said cell.

- 47 -

20. A diagnostic composition, for the identification of a polypeptide comprising the amino acid sequence as depicted in SEQ ID NO:3, comprising the antibody of Claim 12.

21. A diagnostic composition for the identification of a polynucleotide sequence
5 comprising PCR primers derived from SEQ ID NO:1 or allele sequences representative of 11,
12, 13 or 15 GT repeats between positions 2125 and 2152 of SEQ ID NO:1.

10

15

- 1 -

Sequence Listing

5

<110> ZENECA Limited

10

<120> HUMAN RECEPTOR TYROSINE KINASE

<130> 70332/US.Substantive

<150> US 60/088,958

<151> 1998-06-11

15

<160> 6

<170> FastSEQ for Windows Version 3.0

20

<210> 1

<211> 2607

<212> DNA

<213> Homo Sapiens

25

<400> 1

30

35

40

45

50

55

60

65

70

gaggaggagac	acggaattac	tcacagctgt	gctgtgtgca	ttctctgtgg	gcctagcagg	60
gaaggggaca	gccctgtggc	aatgggcatg	acacggatgc	tcctggaatg	cagtctcagt	120
gacaaagtgt	gtgtcatcca	ggagaagcag	tatgaagtga	ttatcgtccc	aactttgttg	180
gttactatct	tcctcatcct	tcttggggtc	atcctgtggc	tttttatcag	agaacaaaga	240
actcaacagc	agcgttcttg	acctcaaggc	attgcccttg	ttcctccacc	tagggacctt	300
agctgggaag	caggacatgg	aggaaatgtg	gctttgccac	ttaaggagac	atccgtggaa	360
aactttcttg	gagctaccac	acctgccctg	gctaagctgc	aggtgccgcg	ggagcaactc	420
tctgaagtcc	tggagcagat	ttgcagtggg	agctgtgggc	ccatctttcg	agccaatatg	480
aacactgggg	accctttctaa	gccaagaggt	gttattctca	aggctttaaa	agaaccagct	540
gggctccatg	aggtacaaga	tttcttaggg	cgaatccaat	tccatcaata	cctggggaaa	600
cacaaaaacc	tgggtgcagct	ggaaggctgc	tgcactgaaa	agctgccact	ctatatgggtg	660
ttggaggatg	tggcccaggg	ggacctgctc	ggctttctct	ggacctgtcg	gcgggatgtg	720
atgactatgg	atggctcttct	ctatgatctc	acagaaaaac	aagtatatca	catcggaag	780
caggtccttt	tggcgctgga	attcctgcag	gagaagcatt	tgttccatgg	ggatgtggca	840
gccaggaata	ttctgatgca	aagtgatctc	actgctaagc	tctgtggatt	aggcctggct	900
tatgaagtct	acacccgagg	ggccatctcc	tctactcaaa	ccatacctct	caagtggcct	960
gccccagAAC	ggcttctcct	gagacctgct	agcatcagag	cagatgtctg	gtcttttggg	1020
atcctgctct	atgagatggt	gactctagga	gcaccaccgt	atcctgaagt	ccctcctacc	1080
agcatcctag	agcatctcca	aagaaggaaa	atcatgaaga	gacccagtag	ctgcacacat	1140
accatgtaca	gtatcatgaa	gtcctgtggg	cgctggcggtg	aggctgaccg	cccctcacct	1200
agagagctgc	gcttgcgcct	agaagctgcc	attaaaaactg	cagatgacga	ggctgtgtta	1260
caagtaccag	agttgggtgtg	acctgaactg	tatgcagctg	tggccggcat	cagagtggag	1320
agcctcttct	acaactatag	catgtcttga	agagtctcgg	gcaagaaaca	ttcatgcata	1380
agtatatgtt	cttggaaatca	attcctctaa	gaacagagaa	tggctcttcc	cagggacaca	1440
aagggagaaa	tgggacatgg	attccttgatc	ttcctttaca	catttctcgg	gaaatctgaa	1500
atgatgtctg	atgggactct	acacatcctg	agctaagaca	tactgtcagt	ctcacttctg	1560
ctgtcccagt	cctagaaatc	ctgggtagaa	gtggtggacc	tgtgcaaagg	aggttttaga	1620
actctgcagt	atttgttggg	gcatggcaca	aataagctca	tcctctccgt	ccgaggctag	1680
tttctctctg	aaccacattt	ttatctagat	gaaaatttgg	aatgaaatga	aggaatagaa	1740
atccaataaa	agagttgaag	ggaaagaaaa	tttaagggttc	ttcttgctca	ggattacaga	1800
tatggaccaa	cacctccttc	aagaaaaggt	ggtaggacac	aaagtctctc	agtcctgagc	1860
cctacatgtg	gggctggagg	agaactataa	cggaaaaaac	tctgagtttc	accttaggta	1920
tagataaaag	aaagatggtc	cccttttatc	tgattctgag	acaggtaaat	tctgtttggt	1980
actacgttta	attagaaggt	ggaggagtca	tttcatgatt	aagaacattc	aacatgtatt	2040
gttcattaa	cttagcttcc	agttccgatt	agactaaagg	gactaagcct	agagagtcaa	2100
tgttagaaca	gtgaaaagaa	ttctgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgcacaata	2160
aataggaaat	gtagaaacca	agcaagaagg	cttagtagct	cagttcttaa	caagggttag	2220
aaaagaatgt	aatctgatat	ggaaggatag	cagcttctaa	ttttcaatca	tctgttgata	2280
tactgtgaaa	cttattttat	taaatttaata	tttattaaat	ggaaatatgc	tttcttggtt	2340
tataactact	aaaaatatca	tagggaggat	aaaagtaaat	aagtgaaggt	taatgccaat	2400
agaaaaattc	aagagataat	gtacaatgtc	agaaaaagga	ttctttatgt	gtaaatgggg	2460
ataaacctta	tttcacaagg	ttgttytgag	gattgatcacg	ttttgagtat	gtatttgtag	2520
actatctggc	acatatgcgc	tcaataaacg	tgtttctcct	taaaaaaaaa	aaaaaaaaaa	2580
aaaaaaaaaa	aaaaaaaaaa	aaaaaaa				2607

- 2 -

	<210> 2	
	<211> 1269	
	<212> DNA	
	<213> Homo Sapiens	
5	<400> 2	
	atgggcatga cacggatgct cctggaatgc agtctcagtg acaagttgtg tgtcatccag 60	
	gagaagcagtg atgaagtgat tatcgccccca actttgttgg ttactatctt cctcatcctt 120	
	cttgggggtca tcctgtgggt ttttatcaga gaacaaagaa ctcaacagca gcgttcttga 180	
10	cctcaaggca ttgccctgt tcctccacct agggacctaa gctgggaagc aggacatgga 240	
	ggaaatgtgg ctttgccact taaggagaca tccgtggaaa actttctggg agctaccaca 300	
	cctgccctgg ctaagctgca ggtgccgcgg gagcaactct ctgaagttct ggagcagatt 360	
	tgcagtggta cctgtgggcc catctttcga gccaatatga acactgggga cccttctaag 420	
	cccaagagtg ttattctcaa ggcttttaaaa gaaccagctg ggctccatga ggtacaagat 480	
15	ttcttagggc gaatccaatt ccatcaatac ctggggaaac acaaaaacct ggtgcagctg 540	
	gaaggctgct gcaactgaaaa gctgccactc tatatggtgt tggaggatgt ggcccagggg 600	
	gacctgtctg gctttctctg gacctgtcgg cgggatgtga tgactatgga tgggtcttctc 660	
	tatgatctca cagaaaaaca agtatatcac atcggaaagc aggtcctttt ggcgctggaa 720	
	ttcctgcagg agaagcattt gttccatggg gatgtggcag ccaggaatat tctgatgcaa 780	
20	agtgatctca ctgctaagct ctgtggatta ggctggctt atgaagttta caccagaggg 840	
	gccatctcct ctactcaaac catacctctc aagtggttg cccagaacg gcttctcttg 900	
	agacctgcta gcatcagagc agatgtctgg tcttttggga tcctgtctta tgagatggtg 960	
	actctaggag caccaccgta tcctgaagtc cctcctacca gcatcctaga gcatctccaa 1020	
	agaaggaaaa tcataagag acccagtagc tgcacacata ccatgtacag tatcatgaag 1080	
25	tcctgtgggc gctggcgtga ggctgaccgc ccctcaccta gagagctgcg cttgcgccta 1140	
	gaagctgccca ttaaaactgc agatgacgag gctgtgttac aagtaccaga gttggtggtg 1200	
	cctgaactgt atgcagctgt ggccggcatc agagtggaga gcctcttcta caactatagc 1260	
	atgctttga	1269
30	<210> 3	
	<211> 422	
	<212> PRT	
	<213> Homo Sapiens	
35	<400> 3	
	Met Gly Met Thr Arg Met Leu Leu Glu Cys Ser Leu Ser Asp Lys Leu	
	1 5 10 15	
	Cys Val Ile Gln Glu Lys Gln Tyr Glu Val Ile Ile Val Pro Thr Leu	
	20 25 30	
40	Leu Val Thr Ile Phe Leu Ile Leu Leu Gly Val Ile Leu Trp Leu Phe	
	35 40 45	
	Ile Arg Glu Gln Arg Thr Gln Gln Arg Ser Gly Pro Gln Gly Ile	
	50 55 60	
45	Ala Pro Val Pro Pro Pro Arg Asp Leu Ser Trp Glu Ala Gly His Gly	
	65 70 75 80	
	Gly Asn Val Ala Leu Pro Leu Lys Glu Thr Ser Val Glu Asn Phe Leu	
	85 90 95	
	Gly Ala Thr Thr Pro Ala Leu Ala Lys Leu Gln Val Pro Arg Glu Gln	
	100 105 110	
50	Leu Ser Glu Val Leu Glu Gln Ile Cys Ser Gly Ser Cys Gly Pro Ile	
	115 120 125	
	Phe Arg Ala Asn Met Asn Thr Gly Asp Pro Ser Lys Pro Lys Ser Val	
	130 135 140	
	Ile Leu Lys Ala Leu Lys Glu Pro Ala Gly Leu His Glu Val Gln Asp	
55	145 150 155 160	
	Phe Leu Gly Arg Ile Gln Phe His Gln Tyr Leu Gly Lys His Lys Asn	
	165 170 175	
	Leu Val Gln Leu Glu Gly Cys Cys Thr Glu Lys Leu Pro Leu Tyr Met	
	180 185 190	
60	Val Leu Glu Asp Val Ala Gln Gly Asp Leu Leu Gly Phe Leu Trp Thr	
	195 200 205	
	Cys Arg Arg Asp Val Met Thr Met Asp Gly Leu Leu Tyr Asp Leu Thr	
	210 215 220	
	Glu Lys Gln Val Tyr His Ile Gly Lys Gln Val Leu Leu Ala Leu Glu	
65	225 230 235 240	
	Phe Leu Gln Glu Lys His Leu Phe His Gly Asp Val Ala Ala Arg Asn	
	245 250 255	
	Ile Leu Met Gln Ser Asp Leu Thr Ala Lys Leu Cys Gly Leu Gly Leu	
	260 265 270	
70	Ala Tyr Glu Val Tyr Thr Arg Gly Ala Ile Ser Ser Thr Gln Thr Ile	

- 3 -

275 280 285
 Pro Leu Lys Trp Leu Ala Pro Glu Arg Leu Leu Leu Arg Pro Ala Ser
 290 295 300
 5 Ile Arg Ala Asp Val Trp Ser Phe Gly Ile Leu Leu Tyr Glu Met Val
 305 310 315 320
 Thr Leu Gly Ala Pro Pro Tyr Pro Glu Val Pro Pro Thr Ser Ile Leu
 325 330 335
 Glu His Leu Gln Arg Arg Lys Ile Met Lys Arg Pro Ser Ser Cys Thr
 340 345 350
 10 His Thr Met Tyr Ser Ile Met Lys Ser Cys Trp Arg Trp Arg Glu Ala
 355 360 365
 Asp Arg Pro Ser Pro Arg Glu Leu Arg Leu Arg Leu Glu Ala Ala Ile
 370 375 380
 15 Lys Thr Ala Asp Asp Glu Ala Val Leu Gln Val Pro Glu Leu Val Val
 385 390 395 400
 Pro Glu Leu Tyr Ala Ala Val Ala Gly Ile Arg Val Glu Ser Leu Phe
 405 410 415
 Tyr Asn Tyr Ser Met Leu
 420

20
 <210> 4
 <211> 15
 <212> PRT
 <213> Homo Sapiens
 25

 <400> 4
 Glu Ala Asp Arg Pro Ser Pro Arg Glu Leu Arg Leu Arg Leu Glu
 1 5 10 15

30
 <210> 5
 <211> 27
 <212> DNA
 <213> Artificial Sequence

35
 <220>
 <223> PCR Primer

 <400> 5
 gccgtcgact gtgggcctag cagggaa 27

40
 <210> 6
 <211> 27
 <212> DNA
 <213> Artificial Sequence

45
 <220>
 <223> PCR Primer

 <400> 6
 gccgcggccg ctcaaagcat gctatag 27

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01798

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/11 C07K14/705 C07K16/18 C12Q1/02
C12Q1/68 A61K48/00 G01N33/53 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARRA ET AL: "The WashU-HHMI mouse EST project" EMBL ACC NO AA098024, 27 October 1996 (1996-10-27), XP002118088	1
A	the whole document	1-21
X	AUFFRAY ET AL.: "IMAGE: integrated molecular analysis of the human genome and its expression" EMBL ACC NO Z42722, 6 November 1994 (1994-11-06), XP002118089	1
	the whole document	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 October 1999

Date of mailing of the international search report

21/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van Klompenburg, W

INTERNATIONAL SEARCH REPORT

International Application No

PC/GB 99/01798

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SHAWVER ET AL.: "Receptor tyrosine kinases as targets for inhibition of angiogenesis" DRUG DISCOVERY TODAY, vol. 2, no. 2, 1997, page 50 XP002118090 cited in the application	16, 17
A	page 58 -page 62; figure 6; table 1	1-15, 18-21
A	--- WO 97 34920 A (SUGEN INC) 25 September 1997 (1997-09-25) page 33, line 18 -page 55, line 31; claims 1-20; tables 1-5	14-17
A	--- RUBIN GRANDIS ET AL.: "Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells" ONCOGENE, vol. 15, no. 4, 1997, pages 409-416, XP002118091 page 414 -page 416, column 1; figures 1-6	7, 8, 12, 14-17, 19, 20
A	--- CHOU ET AL.: "Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 4, 5 February 1987 (1987-02-05), pages 1842-1847, XP002118092 page 1843 -page 1846; figures 2-5, 7, 8	3, 4
A	--- WO 95 30331 A (UNIV PENNSYLVANIA ; GREENE MARK I (US); QIAN XIAOLAN (US)) 16 November 1995 (1995-11-16) page 3, line 21 -page 4, line 10 page 10, line 22 -page 11, line 28 examples 1, 2	3, 4

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB 99/01798

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 17 which is directed to a method of treatment of the human /animal body, and for claims 18 and 19 in so far as they are directed to such a method, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 16 and 17 relate to compounds modulating the activity of the polypeptide without giving a true technical characterization. In consequence, the scope of said claims is ambiguous and vague, and their subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT)

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01798

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9734920	A	25-09-1997	AU	2066797 A	10-10-1997
WO 9530331	A	16-11-1995	EP	0758196 A	19-02-1997
			US	5837523 A	17-11-1998